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ABSTRACT 
Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth 
most common cause of death in the developed Western countries.  
Adoptive T-cell transfer (ACT) refers to an immunotherapeutic approach in which 
anti-tumor T lymphocytes, usually the tumor infiltrating lymphocytes (TIL), are 
identified, grown ex vivo and then re-infused into the cancer patient. 
ACT of EBV-specific T-cell lines and T Cytotoxic Lymphocytes (CTLs) for the 
therapy of EBV-induced lymphomas is the best demonstration of clinically 
efficacious ACT, but there are many evidences also for leukemia and multiple 
myeloma. 
As regards to the solid tumors, ACT using autologous TIL, grown ex-vivo and then 
re-infused into the cancer patient, has emerged as an effective treatment for 
metastatic melanoma and renal cell carcinoma (RCC), that are the most 
immunogenic tumors in humans. Randomized clinical trials are ongoing for gastric 
cancer, hepatocellular carcinoma and lung cancer.  
These approaches mainly use the TIL and the definition of tumor associated 
antigen (TAA), tumor specific antigen (TSA) or  cancer testis antigen (CTA), that 
are generally correlated with tumor progression and immunogenicity in various 
types of cancer.  
However these antigens are often found to be poorly expressed in CRC, and few is 
known about their relationship with this type of neoplasia. In addition, although a 
clear association between TIL and clinical outcome of CRC has been documented, 
active and adoptive immunotherapy do not play yet an important role in the 
treatment of advanced CRC. 
In order to develop an ACT protocol for CRC treatment, we designed an 
experimental approach that does not require neither the definition of molecular 
defined tumor antigens, nor the availability of TIL. Our strategy was based on the in 
vitro stimulation of patient’s CD8
+
-enriched T-cells from peripheral blood 
mononuclear cells (PBMCs) with dendritic cells (DCs), pulsed with apoptotic tumor 
cells as a source of tumor antigens, in order to generate autologous CTLs with 
strong anti-tumor activity. 
In this study, 78 CRC patients were enrolled. Tumor biopsies were obtained at 
surgery, together with 100 ml of heparinized peripheral blood (PB). Tumors were 
mechanically dissociated to a single-cell suspension and cultured to obtain tumor 
cell line from each patient. DCs were generated from previously separated PBMCs, 
using a magnetic positive selection of CD14
+
 monocytes, cultured in presence of 
recombinant human Interleukin-4 (rh IL-4) and recombinant human Granulocyte-
Macrophage Colony-Stimulating Factor (rh GM-CSF). Anti-tumor CTLs were 
elicited in co/micro-culture using DCs as antigen-presenting cells, autologous 
apoptotic tumor cells as source of antigens and T CD8
+
 lymphocytes enriched 
effectors, with weekly stimulation. CTLs Interferon-γ (IFN-γ) secretion was 
assessed by ELISpot assay to evaluate their activation in response to autologous 
tumor. 
Tumor cell lines were obtained from 20 out of 78 patients (25,6%), because gut 
intestinal flora had adversly affected the establishment of primary tumor cell line 
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and a loss of expansion of tumor cells was observed. DCs were generated from 26 
patients, but only 6 patients had the corresponding tumor cell line, indispensable 
for the co-culture setting up. This was the reason why co/micro-cultures were set 
up only for 6 patients. ELISpot assay was performed at the end of co/micro-culture 
stimulations to evaluate effectors IFN-γ secretion. ELISpot results showed that 
strong and significant IFN-γ secretion was detected at the third, fourth and fifth 
stimulations for one patient and at the second for another patient, whereas for 
three patients a weak secretion was detected during the second and third 
stimulations.  
Although our immunological study must be performed on an increased number of 
CRC patients, and the CTLs expansion, together with CTLs lytic ability against 
autologous tumor cells, must be still performed, our results suggested that the 
generation of tumor-specific CTLs could be useful for supporting an ACT approach 
in CRC. 
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RIASSUNTO 
Il carcinoma del colon retto (CRC) è il terzo tipo di tumore più frequente al mondo e 
la quarta causa di morte per tumore nei paesi Occidentali.  
La terapia cellulare adottiva (o trasferimento adottivo di cellule T) (ACT) è un 
approccio immunoterapeutico in cui, i linfociti T con attività anti-tumorale, 
generalmente i linfociti T infiltranti il tumore (TIL), vengono identificati, espansi ex 
vivo e reinfusi nel paziente neoplastico. 
La migliore dimostrazione di efficacia clinica della ACT è stata ottenuta nei linfomi 
associati al virus di Epstein Barr (EBV), utilizzando linee di cellule T-EBV 
specifiche e linfociti T citotossici (CTLs), ma buoni risultati sono stati ottenuti anche 
per diversi tipi di leucemie e per il mieloma multiplo. 
Per quanto riguarda i tumori solidi, la ACT, utilizzando TIL espansi ex vivo e poi 
reinfusi nel paziente, si è rivelata un trattamento terapeutico efficace per pazienti 
affetti da due tumori particolarmente immunogenici quali il melanoma e il 
carcinoma a cellule renali (RCC). Studi clinici di ACT sono attualmente in fase di 
sperimentazione  per il carcinoma gastrico, il carcinoma epatocellulare e il cancro 
del polmone. 
Questi approcci sfruttano principalmente l’utilizzo di TIL e l’identificazione di 
antigeni tumore associati (TAA), antigeni tumore specifici (TSA) o degli antigeni del 
cancro testicolare (CTA), dal momento che essi sono generalmente correlati con la 
progressione neoplastica e con l’immunogenicità di diversi tipi di tumore. 
Tuttavia, questi antigeni sono spesso poco espressi nel CRC e le loro interazioni 
con questo tipo di tumore sono ancora poco definite. 
In aggiunta, sebbene sia stata riportata una chiara associazione tra TIL e 
“outcome” clinico nei pazienti affetti da CRC, sia gli approcci di immunoterapia 
attiva che adottiva non giocano ancora un ruolo chiave nel trattamento del CRC in 
fase avanzata. 
Per sviluppare un protocollo di ACT nel CRC, abbiamo disegnato un approccio 
sperimentale che non necessita nè dell’identificazione di antigeni tumorali 
molecolarmente definiti, nè dell’isolamento dei TIL. La nostra strategia prevede la 
stimolazione dei linfociti T CD8
+
  del paziente, ottenuti a partire dall’isolamento 
delle cellule mononucleate del sangue periferico (PBMCs), con le cellule 
dendritiche (DCs) dello stesso paziente, pulsate con le cellule tumorali autologhe 
condotte in apoptosi per avere una fonte eterogenea di antigeni tumorali, al fine di 
generare ex-vivo CTLs con una forte attività antitumorale. 
Nel nostro studio sono stati arruolati 78 pazienti affetti da CRC. Le biopsie tumorali 
sono state prelevate in sede operatoria, contemporaneamente ad un prelievo di 
sangue periferico di circa 100 mL. 
Il tumore è stato dissociato meccanicamente fino ad ottenere una sospensione 
cellulare, che è stata poi messa in coltura per l’ottenimento di linee cellulari 
primarie tumorali da ciascun paziente. Le DCs sono state prodotte a partire dalla 
differenziazione dei monociti, isolati magneticamente con beads CD14
+
 dai 
PBMCs, coltivati in presenza di Interleuchina 4 ricombinante umana (rh IL-4) e del 
Fattore stimolante le colonie granulocitarie-macrofagiche ricombinante umano (rh 
GM-CSF).  
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Si è quindi cercato di favorire l’attivazione dei CTLs autologhi contro il tumore co-
coltivandoli con le DCs, le cellule presentanti l’antigene per eccellenza, caricate 
con cellule tumorali apoptotiche, che costituiscono la nostra fonte eterogenea di 
antigeni tumorali, attraverso stimolazioni settimanali ed in presenza di opportuni 
mediatori. Per valutare la secrezione di Interferon-γ (IFN-γ) da parte dei CTLs, e 
quindi la loro attivazione in risposta al tumore, è stato utilizzato il saggio 
immunoenzimatico ELISpot.  
Le linee cellulari tumorali sono state ottenute da 20 pazienti su 78 arruolati, poichè 
la flora intestinale da un lato, e una mancata espansione cellulare dall’altro, ne 
hanno compromesso l’ottenimento. Le DCs sono state generate da 26 pazienti, ma 
soltanto per 6 pazienti è stata ottenuta la corrispondente linea cellulare tumorale 
con cui poter allestire la co-coltura. Questo è il motivo per cui sono state allestite 
solo 6 co-colture e il test ELISpot è stato quindi effettuato per valutare la 
secrezione di IFN- γ a partire dalla fine delle stimolazioni settimanali degli effettori 
di questi 6 pazienti. I risultati del saggio ELISpot hanno mostrato una forte e 
significativa secrezione di IFN-γ alla terza, alla quarta e alla quinta stimolazione per 
un paziente, e alla seconda per un altro paziente, mentre in 3 pazienti una debole 
secrezione della citochina è stata riscontrata durante la seconda e la terza 
stimolazione.  
Sebbene il nostro studio immunologico debba essere condotto su una più ampia 
casistica di pazienti affetti da CRC, e l’espansione dei CTLs, così come la loro 
capacità litica nei confronti delle cellule tumorali autologhe debba essere ancora 
messa a punto, i nostri risultati ci suggeriscono che l’ottenimento di CTLs tumore-
specifici potrebbe essere molto utile per supportare approcci di ACT nel CRC.
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1.1 Colorectal cancer 
1.1.1 Epidemiological features 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers 
worldwide (Figure 1). It affects the bowel and the rectum and is rare in 
people under 40, with almost 85% of cases being diagnosed in persons 
over 65 years of age [Ferlay et al., 2008, WHO, 2008]. The latest data 
collected in the United States from the American Cancer Society’s show 
about 103,170 new cases of CRC for 2012 [Chen at al., 2012]. CRC 
incidence is the same for man and women, while it is the third common 
type of cancer in men, after the prostate and lung cancer, and the second 
most common cancer in women after breast cancer [Ferlay et al., 2008, 
WHO 2008]. Even if CRC mortality has decreased over the last 20 years, it 
remains the third cause of cancer related mortality, accounting for 
approximately 600,000 deaths in 2008 worldwide [Antonic et al., 2013].  
                          
Fig. 1: Prevalence of CRC around the word per 100,000 people [Bingham et al., 2004]. 
Countries with a high incidence of colon cancer are indicated with blue (North America, 
Australia); countries with moderate levels in pink or red; and countries with low incidence in 
green (Asia, Africa). 
 
1.1.2 Colorectal cancer classification, risk factors and genetic profile 
Researchers have found several risk factors that may increase a person's 
chance of developing colorectal polyps or CRC. However, even if a person 
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with CRC has a risk factor, it is often very hard to know how much that risk 
factor may have contributed to the cancer. 
Age, personal history, family history, racial and ethnic background are the 
most important components identified. In addition, life style and diet related 
factors also contribute to the development of CRC as well [Slattery et al., 
2000]. CRC can be divided in three subtypes of cancer, depending on 
whether it is:  
a) sporadic, that constitutes the large amount of all CRC (about 80%); 
b) inheredited, due to genetic instability; 
c) inflammatory, when the development of tumor is successive to the 
presence of chronic inflammations of gastrointestinal tract, which includes 
ulcerative colitis and Crohn’s disease. 
CRC is a paradigm for multistep carcinogenesis with morphological–
genomic associations in the adenoma–adenocarcinoma sequence, as 
introduced by Fearon and Vogelstein in 1990 [Feareon et al., 1990, Muto er 
al., 1975]. The body of evidence indicates that: 1) some alterations 
segregate together or inversely as part of a “genetic pathway” [Ilyas et al., 
1999]; and 2) functional pathways can be disrupted at different points so 
that different alterations may have functional “equivalence” in the same 
pathway [Parsons et al., 2005]. 
The more frequent genetic alteration that could lead to sporadic CRC is the 
somatic mutation in adenomatous polyposis coli (APC) gene that could be 
detected in the 80-85% of the patients with nonhereditary sporadic 
adenomatous polyposis (SAP). Mutation of the APC gene is thought to be 
an early step in the development of CRC [Saif et al.,  2010]. This mutational 
event contributes to the activation of Wnt/βcatenin pathway that actives the 
transcription of genes such as c-myc and cyclin D, involved in cell cycle 
progression.  
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The k-ras gene is one of the oncogenes and it is assumed that the mutation 
occurs after the APC gene in the CRC [Takahashi et al., 2004]; mutation in 
Ras protein usually cause constitutive activation of Ras GTPase, which 
leads to over-activation of downstream signaling pathways, resulting in cell 
transformation and tumorigenesis [Boguski et al.,1993, Rowinsky et al. 
1999, Bos et al., 1987, Forrester et al., 1987]; indeed it was demonstrated 
that activating mutations of k-ras, through the subsequent activation of at 
least 9 pathways [Karnoub et al., 2009], promote cell proliferation, 
transformation and differentiation [Valencia et al., 1991]. It was 
hypothesized that this genetic alteration occurs during the early stage of 
CRC carcinogenesis because the same point mutation was found in the 
same patient’s adenoma and adenocarcinoma, and seems to be related to 
the increasing size of the tumor. Previously studies have shown that, in 
clinical specimens, approximately 30% to 50% of CRC harbored k-ras 
mutations [Bos et al., 1987, Forrester et al., 1987, Andreyev et al., 1998, 
Fox et al., 1998]. 
The accumulation of next genetic changes like the loss of p53 tumor 
suppressor gene could cause the development of invasive CRC [Feareon 
et al., 1990]. This mutation is the most important point that determines the 
borderline between the adenoma and the adenocarcinoma [Takahashi et 
al., 2004] and it is detected in about 75% of CRC patients [Grady et al., 
2002]. 
A minor group of CRC patients (8-15%) is associated with hereditable 
tendency. This group can be divided in two subgroups: the first develop 
familial adenomatous polyposis (FAP), due to a germ line mutation of the 
APC gene, and the lifetime incidence of CRC is almost 100% [Burn et al., 
2012]; the second includes the patients with Hereditary Non-polyposis 
Colorectal Cancer (HNPCC or Lynch Syndromes), in which the genetic 
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anomalies are less defined, but they seem to be associated with mutations 
of several genes involved in the complex mechanism of DNA mismatch 
repair [Saif 2010]. However other rare syndromes, such as MYH-
associated polyposis (MAP), Peutz-Jeghers syndrome (PSJ), and juvenile 
polyposis syndrome (JPS) can also increase CRC risk [Centelles, 2012]. 
1.1.2.1 Infectious agents as risk factors  
The long list of cancer risk factors continues to evolve, and in the past few 
decades has expanded to include infectious agents.  
It has been demonstrated the role of small DNA viruses [polyomaviruses, 
papillomaviruses, and Epstein-Barr virus (EBV)] in the development of 
various types of cancers such as Merkel cell carcinoma, cervical cancer, 
Burkitt’s lymphoma, Hodgkin’s lymphoma, as well the association between 
Helicobater pylori and gastric cancer. 
At now, although several works reported that viruses and bacteria can 
support CRC through direct mutagenesis, secretion of mutagenic products 
and/or prolonged infection and inflammation that leads to increase epithelial 
cell proliferation, they are still not recognize as risk factors. 
However, Tjalsma and colleagues proposed a model, called “driver-
passenger” based on next generation sequencing, in which each stage of 
CRC has a specific pathogen(s) associated with it [Tjalsma et al., 2012], so 
there is a observed anatomic predisposition for development of CRC, which 
can be correlated with the presence and the quantity of bacteria in different 
part of gastrointestinal tracts (colon and small intestine). 
1.1.3 Colorectal cancer staging 
The most common used staging system for CRC is that of the American 
Joint Committee on Cancer (AJCC), known also as the tumor node 
metastasis (TNM) system. Two older staging systems include Duke’s 
6 
 
[Dukes et al., 1932] and Astler-Coller [Astler et al., 1954] but these are very 
rarely used today. 
The meaning of the three letters combined in AJCC system is: 
 T Describes how far the primary tumor has grown in to the wall of 
the intestine and if it has grown also in neighboring areas; 
 N Detects the extent of spread to nearby lymph nodes; 
 M Indicates whether the cancer has metastasized to other organs 
of the body (The more frequent sites of spread in CRC are liver and 
lungs). 
The information from the T, N, M is combined to determine the cancer 
stage grouping from Stage I (the least advanced), to Stage IV (the most 
advanced) (Figure 2).  
 
                       
 
Fig. 2: CRC staging 
http://alamocitycancercouncil.org/uploads/ACCC_ColonBrochure_Spread.pdf 
 
The Stage 0 is very early stage of CRC, where polyps are formed in the 
mucosal lining of the colon. In the Stage I polyp develops into a tumor and 
invades the inner-lining of the mucosa. The Stage II (from A to C) exhibits 
when the cancer has spread beyond colon but not to the lymph nodes 
through metastasis. The Stage III (from A to C) shows a spread of all the 
wall of the colon and of the surrounding lymph nodes. At the Stage IV 
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cancer has speeded to the other organs, like liver, ovary, testis, intestines 
[Mishra et al., 2013] 
The grade of cancer is another factor used to predict the survival of CRC 
patients [Ried et al., 1996]. Grade is a description of how closely the cancer 
looks like normal colorectal tissue when seen under a microscope, and it is 
indicated from G1 to G4 (where the cancer looks very abnormal). It’s 
deducible that high grade cancers tend to grow and to generate metastasis 
more quickly than low grade cancers.  
1.1.4 Methods of diagnosis 
The survival rate changes within the different Stage of CRC, starting from 
the 95% of the Stage I, to the only 3% of the Stage IV. 
Therefore, one of the main objectives is to improve the diagnostic methods 
for CRC, in order to identify the tumors in the early stage of development. 
Methods such as fecal occult blood test, sigmoidoscopy, colonoscopy, 
virtual colonoscopy and double contrast barium enema offered 
improvements in the detection rates of CRCs [Strul et al., 2007]. The main 
limitations of these are: the expensive costs, risks, lack of sensibility in the 
starting phase of tumor and inconvenience to the patients [National Cancer 
Institute Factsheets]. So, identifying the early disease biomarkers and 
setting non-invasive tests, using for example blood or urine, remains a 
research focus. Tumor biomarkers will offer an opportunity to translate 
unique CRC biological features into diagnostically pertinent information and 
would enable personalized treatments. 
1.1.5 Conventional treatments 
The conventional approaches to treating CRC include: polypectomy and 
surgery, radiation therapy, chemotherapy and targeted therapy [Mishra et 
al., 2013]. 
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Polypectomy consists in the surgical removal of the polyps during 
colonscopy. The surgical removal of pre-cancerous/cancerous lesions has 
the potential for full recovery of the patient and can be successful for a 
small and localized tumor outgrown. In addition, surgery is the only way to 
contrast the chemotherapy and radiotherapy resistant tumors.  
Radiotherapy is the careful use of high energy X-rays to control the 
proliferation of malignant cells. This treatment is directed to the tumor area 
and to any neighbouring tissues felt to be at risk of containing tumor cells, 
providing a much larger absorbed dose at the cancer site than in the 
normal tissue. Depending on the location and the stage of CRC, 
radiotherapy is recommended in combination with chemotherapy, before or 
after the surgery. Radiation given before surgery can help shrink tumor, 
while after keep the cancer from coming back. Possible side effects of 
radiation include frequent bowel movements, abdominal pain and 
cramping, rectal discomfort, burning with urination, frequent urination, skin 
irritation and fatigue, but these symptoms in the majority of cases stop at 
the end of therapy. 
The treatment of metastatic cancers mainly relies on chemotherapy, the 
method or process of administering a pharmaceutical compound to kiss 
tumor cells by direct cytotoxicity leading tumor regression. These drugs 
include alkylating agents, antimetabolites, plant alkaloids, antitumor 
antibiotics, enzymes and hormones; these molecules are able to interfere 
with cell division pathways including DNA replication and chromosomal 
separation, and unfortunately are not specific for cancer cells.  Nowadays 
the conventional chemotherapy treatment is based on a combination of 
different drugs, in order to increase the disease free survival. The CRC 
treatments more commonly used and characterized by the administration of 
a drug plus an adjuvant are: 5-fluorouracil (5-FU) plus levamisole, 5FU plus 
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leucovorin, but also the chemotherapy with oxaliplatin and irinotecan is very 
common [Lee et al., 2012]. The development of new targeted drugs, such 
as monoclonal antibodies (mAb) against vascular endothelial growth factor 
(VEGF) and epidermal growth factor receptor (EGFR) seem to add further 
benefits to patients with metastatic CRC [Garret 2011].  
A kind of targeted therapy is a targeted drug delivery system that seeks to 
concentrate anti-cancer agents at the cancer tissue, reducing the relative 
concentration of the medication in the proximal tissue. For example, 
polymeric micelles increase the accumulation of drugs in tumor tissues 
utilizing the enhanced permeability and retention effect [Matsumura et al., 
2008]. The main advantages of micelle are the possibility to modify their 
diameter, to be sure that they not pass in normal vessel walls, and to 
incorporate a variety of drugs. 
The chemoprevention of CRC is another strategy to reducing the morbidity 
and the mortality from this disease; indeed, CRC has a natural history of 
transition from normal crypts through adenoma to overt a carcinoma, that 
could be arise in a time frame of 10-20 years, providing a window of 
opportunity for effective intervention and prevention; in addition, the 
occurrence and recurrence of CRC after treatment is still very high. 
Chemoprevention is defined as the use of specific natural or synthetic 
chemical agents to reverse, suppress or prevent the transition from 
adenoma to invasive CRC. It has been shown that chronic intake of 
traditional non-steroidal anti-inflammatory drugs could reduce the incidence 
of CRC [Klampfer et al., 2011, Hawk et al., 2003]. In addition, 
cyclooxygenase-2 (COX-2) inhibitors have been approved by Food and 
Drugs Administration (FDA), following the evidence that they are effective 
in reducing CRC in animal models and FAP patients [Bakhle et al., 2001]. 
Chemoprevention is thus of particular importance to genetically 
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predisposed patients and to those patients who are especially susceptible 
to the environmental causes of CRC [Tanaka et al., 1997 and 2009]. A lot 
of other pharmacological and non-pharmacological agents have been 
analyzed to define their potential as chemiopreventive agents for CRC 
[Gwyn et al., 2002]; among them, there are irreversible inhibitor of ornithine 
decarboxylase, calcium, folate, vitamins selenium and its derivates, and 
dietary fiber. Even if the exact action mechanisms of these agents are not 
fully understood, five potential pathways and mechanisms of these 
composts have been illustrated: a) increased sensitivity of cancerous cells 
to apoptosis, b) inhibition of angiogenesis, c) modulation of inflammation 
and immune response, d) decreased metastasis and e) inhibition and 
removal of endogen carcinogen formation in vivo [Hawk et al., 2003, 
Dempke et al., 2001, Prescott et al., 2000, Subbaramaiah et al., 2003]. The 
impact of these molecules could improve the treatment and the prevention 
of CRC.  
1.2 Cancer immunotherapy 
The discovery that the cells of the immune system can help fighting against 
cancer does the groundwork for the development of immunotherapeutic 
approaches. As is known, people with weakened immune system are more 
likely to get certain cancers. Anyway, also people with normal immune 
system can develop cancer when the immune system fail to recognize 
cancer cells as foreign agents, or when the cancer cells do not express 
their antigens which are different from these of normal cells. In other cases 
the response of the immune system can be detected, but it is often too 
weak to induce apoptosis in cancer cells, or the cancer cells themselves 
may also secret immunosuppressants that may keep the immune system in 
check [Mishra et al., 2013]. For these reasons, one of the main topic of 
researchers was, and is still today, designing a way to help the immune 
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system to recognize cancer cells and strengthen its response so that it can 
destroy the cancer cells. 
1.2.1 A historical overview on cancer immunotherapy 
Several discoveries have accompanied the development of immunotherapy 
as new branch of medicine for cancer treatments. Without mentioning the 
main immunological findings and without going too far back in time, we take 
the discovery in 1976 of recombinant human Interleukin 2 (rh IL-2) as T-cell 
growth factor in vitro [Morgan et al., 1976 ] the starting point of our historical 
travel in this topic. In 1985 it was demonstrated that the administration of rh 
IL-2 to patients could mediate the regression of invasive human cancer, 
providing the first evidence that the manipulation of human immune system 
could drive to tumor regression [Rosenberg et al., 1985]. This encouraging 
data have determined the FDA acceptance of rh IL-2 as drug for the 
treatment of patients with metastatic RCC and metastatic melanoma, the 
most immunogenic human tumors, in 1992 and 1998 respectively [Smith et 
al., 2008]. The discover of the first tumor antigen in 1991 [Van der Bruggen 
et al., 1991] leads off to the description of hundreds of antigens and 
antigenic epitopes expressed on cancer cells and recognized by the 
immune system [Rosenberg et al., 1999, Robbins et al., 2000] in the next 
two decades, with the aim to change over a specific immunotherapeutic 
approaches. These have led to a myriad of clinical trials assessing 
immunization with peptides, proteins, dendritic cells (DCs), recombinant 
viruses, whole cells and plasmidic DNA; most of them have demonstrated 
clinical benefits for patients, as for example the results obtained by Kantoff 
[Kantoff et al., 2010] after the immunization of prostate cancer patients with 
DCs. The difficulties observed to obtain efficient vaccines, including the 
inability to generate in vivo a large number of antitumor T-cells with high 
affinity for tumor antigen, as well as the potential immunosuppressant 
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function of tumor microenvironment [Rosenberg et al., 2005], have lead to 
develop other immunotherapeutic approaches. Indeed, some of that 
obstacles can be overlap by the use of adoptive cellular therapy (ACT), 
based on the administration of antitumor immune cell in patients with 
metastatic cancers and there are best evidences of its success [Dudley et 
al., 2002 and 2008 Rosenberg et al.,  2008]. Although the more comforting 
results were obtained on melanoma patients, there are promising evidence 
of this approach also for other kinds of malignancies such as: EBV-induced 
lymphoma [Rooney et al., 1998], nasopharyngeal carcinoma  [Straathof et 
al., 2005(a)], neuroblastoma [Pule et al.,  2008], metastatic synovial 
sarcoma [Robbins et al., 2011] and metastatic CRC [Parkhuirst et al.,  
2011]. 
1.2.2 Immunesurveillance against tumor 
The human organism has a number of different types of immune cells to 
effectively deal with transformed cells and foreign invaders such as viruses 
or other microorganisms. The cells mainly involved in this process, called 
“immunosurveillance”, are the T-lymphocytes, able to destroy transformed 
or infected body cells.  
The immunosurveillance theory was formulated for the first time by Burnet 
in 1970 [Burnet, 1970]. Burned postulated that the development of T-cells 
mediated immunity during evolution was specific for the elimination of 
transformed cells and that T-cells continuously survey the body and 
eliminate those cells that underwent cancerous transformation. After 
several years, new studies reinvigorated and validated the 
immunosurveillance concept [Smyth et al., 2001, Dunn et al., 2002, Dunn et 
al., 2004]; this theory was supported also by Schreiber and colleagues 
[Schreiber et al., 2004] who have been demonstrated the direct role of 
lymphocytes and of the cytokine Interferon γ (IFN-γ) in tumor suppression. 
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It is now clear that T-cells are efficient at eliminating virus-induced 
malignancies, but the response to chemical or physical carcinogen-induced 
tumors, as it has been shown in animal models, is much weaker. This 
difference in response is primarily related to the nature of the antigen. The 
transformed cells must have phenotypical changes to be recognized as 
non-self by T-cells. In addition, even if the changes had occurred, a lot of 
mechanisms to evade the immune system could put in place. As reported 
by Vera and coworkers [Vera et al., 2009], the tumor immune evasion 
strategies include: 
 
a) secretion of immunosuppressive cytokines such as Interleukin-10 
(IL-10), Interleukin-13 (IL-13) and transforming growth factor beta 
(TGF-β), able to inhibit the effector T-cells [Zou et al., 2005]; 
b) expression’s modulation of major histocompatibility complex (MHC) 
molecules and co-stimolatory molecules to prevent antigen-specific 
T-cells recognition [Zou et al., 2005]; 
c) recruitment of regulatory T-cells (T regs) that could inhibit the T 
effectors by direct contact or by secretion of soluble factors [Woo et 
al., 2001, Curiel et al.,  2004, Marshall et al.,  2004]; 
d) constitutive expression of an enzyme that prevents the lymphocytes 
proliferation, called indoleamine 2,3-dioxygenase (IDO) 
[Zamanakou et al.,  2007]; 
e) apoptosis of activated T-cells through the expression of Fas ligand 
(FasL) [Igney et al., 2002]; 
f) expression of inhibitory cell surface molecules such as program 
death ligand (PD-L1), which interacts with PD-1 expressed on 
activated T-cells, and induces T-cell exhaustion [Keir et al., 2008, 
Dotti, 2009]. 
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So that, the immunosurveillance appears as only one dimension of the 
complex relationship between the immune system and cancer [Dunn et al., 
2002 and 2004, Schreiber et al., 2004]. The evidences that the immune 
system may also promote the emergence of primary tumors with reduced 
immunogenicity, able to escape immune recognition and destruction 
[Shankaran et al., 2001] do the groundwork for the cancer immunoediting 
hypothesis [Dunn et al., 2002, and 2004]. 
As clearly reviewed by Dunn and colleagues in 2004, cancer immune-
editing is a dynamic process composed of three phases: elimination, 
equilibrium and escape, in which elimination represents the canonic phase 
of immunosurveillance, equilibrium is the period of immune-mediated 
latency after an incomplete tumor destruction in the elimination phase, and 
escape refers to the final out-growth of tumors that have outstripped 
immunological restraints of the equilibrium phase (Figure 3). 
 
                        
Fig. 3: The Three Phases of the Cancer Immunoediting Process [Dunn 2004] 
 
 
1.2.3 Role of dendritic cells and t cd8+ lymphocytes in cancer 
immunotherapy  
The cells of the immune system on which we have focused our attention 
are: the most important category of antigen presenting cells (APCs), the 
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DCs [Banchereau et al., 1998], and the main cellular type responsible of an 
anti-tumor response, the T CD8+ lymphocytes. 
DCs: are the most potent APCs, essential for the initiation and maintenance 
of immune response [Hart et al., 1997, Gallucci et al., 1999, Steinman, 
1991]. DCs work at the interface between peripheral tissues and lymphoid 
organs. So these cells can be found in many tissues of the human body, as 
a heterogeneous population of specialized APCs, circulating via the blood 
to most of tissue [Steinman et al.,  1973]. 
DCs can be divided in two peripheral blood (PB) DC subsets: 1) lymphoid 
derived DCs, that are CD11c negative and usually express high levels of 
CD123; 2) myeloid derived DCs, that have the opposite surface marker 
expression (CD11c+ , CD123-) [Shortman et al., 2002]. DCs surface antigen 
expression, morphology and function vary in association with their 
maturation or activation status in a given tissue [Hart et al., 1997]. This is 
clearly evident in the circulation: whereas myeloid DCs are adept at antigen 
uptake, they haven’t the typical “dendritic” morphology when freshly 
isolated and they require a period in culture before acquiring  the 
appropriate costimulatory molecules required for an optimal T-cell 
stimulation [Upham et al., 2000]. 
However, DCs have a low concentration in PB (0,01%) and it is very hard 
to identify of a single DC-specific cell marker, so their isolation is very 
difficult from this biological fluid [Syme et al., 2005]. 
Anyway, in physiological conditions, DCs are present in two maturation 
states: immature DCs (iDCs), whose function is to capture, process and 
presenting antigens [Elkord et al., 2005, Brossart et al., 1997, Cella et al., 
1997], and mature DCs (mDCs), which can drive T-cell clonal expansion 
through cell-cell interaction and cytokines production [Elkord et al., 2005, 
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Cella et al., 1997, Steinman et al., 1991, Macatonia et al., 1995, Koch et al., 
1996, Caux et al., 1994].  
Immature DCs, derived from bone marrow precursors check the 
extracellular milieu of peripheral tissues for the presence of pathogens and 
danger signals. After the recognizing of these, DCs became mature by 
pathogen-associated molecular patterns (PAMPs) via Toll like receptors 
(TLRs), and by inflammatory cytokines and prostaglandins released in the 
environment. The DCs maturation is essential for their rapidly migration to 
the afferent lymph nodes, that could be done following a chemokine 
gradient; at least mDCs are able to prime the immune response through 
interaction between CD40 (expressed by DCs) and CD40-ligand 
(expressed by the T-cells) [Nencioni et al., 2008].  
Nowadays it’s clear that DCs play a critical role in the induction of 
protective and therapeutic anti-tumor immunity, by contributing to the 
generation and proliferation of T Cytotoxic lymphocytes (CTLs) and helper 
T-cells (Th cells) [Yasuda et al., 2006]. Studies on murine models have 
been analyzed different strategies to induce an efficient anti-tumor 
immunity with tumor antigen-loaded DCs [Boczkowski et al., 1996, Fields et 
al., 1998, Gong et al., 1997, Mayordomo et al., 1995], that have been 
reported in trials in tumor-bearing patients [Hsu et al., 1996, Nestle et al.,  
1998, Murphy et al., 1999, Kugler et al., 2000]. The strategies used for 
transfer antigens from tumors to DCs for MHC class I presentation, mainly 
derived from in vitro experiments, and as reviewed by Melief  include : 1) 
antigen from dead cells (apoptotic or necrotic tumor cells); 2) soluble 
antigens bound to heat shock protein (HSP); 3)  soluble protein; 4) antigen-
carrying vescicles secreted by some tumor cells called exosomes; 5) 
transfer of small antigenic protein fragments, and two others that involve 
the direct transfer of peptide MHC complex to DCs [Melief, 2008]. The first 
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mechanism has been chosen by us to develop an immunotherapeutic 
approach in CRC. 
T CD8+ lymphocytes: Once activated, these cells are called CTLs and are 
able to directly damage target cells by using at least three distinct effector 
functions: 1) release of preformed toxic substances, such as perforin, 
granzymes, and granulolysin; 2) triggering of programmed cell death, or 
apoptosis, by engagement of Fas receptor with FasL; 3) secretion of 
cytokines such as tumor necrosis factor alpha (TNF-α) and IFN-γ [Fragoso 
et al., 2002]. 
IFN-γ is the typical cytokine with opposing effects on tumors. It has been 
demonstrated that endogenously produced IFN-γ protects the host against 
the growth of transplanted tumors and also the formation of primary 
chemically induced  and spontaneous tumors [Dighe et al.,  1994, Kaplan et 
al., 1998, Shankaran et al.,  2001, Street et al.,  2001 and 2002].  It is an 
inflammatory cytokine that, for example, was up-regulated following 
radiation in a melanoma model [Lugade et al., 2008], and also in other 
cases it has conventionally been had an antagonistic effect on tumor 
growth [Zaidi et al., 2011], even if many studies has investigated a possible 
role of this cytokine in immunosuppression [Taniguchi et al., 1987, 
Gorbacheva et al., 2002, Katz et al., 2008, Prendergast, 2008, Ostrand-
Rosenberg et al., 2009]. However, in a very recent study of Gerber and 
colleagues [Gerber et al., 2013], it was shown that IFN-γ is not only 
beneficial, but essential in mediating the antitumor effects of radiation in a 
mouse colon adenocarcinoma tumor. The levels of IFN-γ increased in 
tumor environment after irradiation and it was confirmed that cytokine 
production was done by CD8+ T lymphocytes. Indeed, elimination of CD8+ 
T-cells not only greatly reduce the intratumoral concentration of IFN-γ, but 
also abrogated any antitumor effect of radiation. The finally consideration of 
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Gerber et al was that although the cytokine had no direct effect on tumor 
cells in promoting tumor control, IFN-γ enhance the cytolytic capacity of T-
cells, possibly in an autocrine manner, resulting in a decrease of tumor 
burden [Gerber et al., 2013].   
The secretion of IFN-γ was our main parameter to evaluate a specific CTLs 
antitumor response.  
1.2.4 Tumor antigens: features and classification 
In the last decades, different studies focused their attention on the definition 
and classification of tumor antigens. 
Two class of non-viral tumor antigen have been identified: 1) tumor-specific 
antigen (TSA), that are caused by somatic mutations, able to alter self-
proteins through single amino acid substitutions, truncation, deletion or 
fusion to other protein; these antigens are expressed by autologous cancer 
cells but not by autologous normal control tissues or by allogenic cancer 
cells, so they are truly tumor specific [Oettgen et al., 1990]; 2) tumor-
associated shared antigens (TAA) that result from an aberrant expression 
of non-mutated proteins [Schreiber et al., 2003, Dermime et al., 2004]; they 
are found on autologous and allogenic cancer cells as well on a subset of 
normal cells [Oettgen et al., 1990]. 
TSA have two specific advantages compared to TAA: the first is their 
exclusively expression on cancer cells, minimizing the risk of autoimmune 
destruction. Additionally there is no neonatal or peripheral tolerance to 
these antigens prior to tumor development, since the immune system has 
not been previously exposed to them. The second is that many of these 
TSA results in mutated proteins essential for the tumorigenic process. It 
means that those proteins, required to maintain the malignant phenotype, 
are less likely to get lost during tumor progression, even under the selective 
pressure of anti-cancer treatment, such as cancer immunotherapy [Sensi et 
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al., 2005 and 2006]. Conversely, targeting TAA, that are not essential in 
tumor development, could determine the formation of antigen loss variants 
[Lozupone et al.,  2003, Maeurer et al., 1996, Jager et al., 1996, Yee et al., 
2002]. 
Several works have been demonstrated that there is a sort of hierarchical 
immune response in the hosts: TSA were found to be immunodominant, 
while TAA were defined as immunorecessive. The disadvantage of TAA is 
that they could induce an immune response only when the immune 
dominant antigens are lost [Wortzel et al., 1983, Dudley et al., 1996]. 
TSA are the ideal targets of anti-cancer therapy for the reasons listed 
beforehand, but targeting these antigens would determine a much 
expensive and personalized therapy for patients, so researchers are 
making an effort to identify molecules that could be expressed not only from 
one patient with a specific kind of tumor, but from several tumors. 
A third class of tumor antigens was identified, through serological 
investigations: these antigens are cell surface molecules widely expressed 
by normal or non-malignanT-cells, and their precise nature or biochemical 
origin is elusive [Furukawa et al., 1989] 
The progresses of several molecular technologies, such as serological 
analysis of recombinant cDNA expression library (SEREX), microarray 
technologies etc., allowed the identification of many tumor antigens. 
In the review of Schietinger and colleagues [Schietinger et al., 2008], TAA 
were subdivided in four categories, according to their expression pattern: 
 
1) Oncospermatogonal antigens (cancer-testis antigens or CTA): 
cancer cells express these antigens that are normally found on 
spermatocyts/spermatogonia [such as melanoma associated 
antigen (MAGE) and antigens derived from the GAGE, BAGE and 
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NY-ESO-1 genes], but also on fetal ovary [Koslowski et al., 2004] 
and sometimes in placental trophoblasts [Jungbluth et al., 2007]. 
CTA are found variably in a range of cancers, including about 90% 
of melanomas [Zendman et al., 2003] and melanoma associated 
antigen A1 (MAGEA1) became the prototype of this class of 
molecules with a highly restricted tissue expression [Simpson et al., 
2005].  
2) Differentiation antigens: are molecules expressed on non-malignant 
cells of the same cell lineage as the tumor [tyrosinase related 
protein-1 (TRP-1), glycoprotein 100 (gp100), melanoma antigen 
recognized by T-cells 1 (MART-1), CD20 and epithelial cell 
adhesion molecule (EpCAM)]; 
3) Oncofetal antigens: these antigens can be found on embryonic and 
fetal tissue as well as as certains cancers [alpha-fetoprotein (AFP), 
carcinoembryonic antigen (CEA) and 5T4] 
4) Over-expressed antigens: are normal proteins whose expression is 
up-regulated in cancer cells [prostate specific antigen (PSA), wilde 
type p53, human epidermal growth factor receptor 2 (Her2/Neu) and 
EGFR] 
Then usually, the expression of tumor antigens on cancer cells permits T-
cells to recognize, bind and destroy tumor cells. 
The vast majority of T lymphocytes express on their surface a T-cell 
receptor (TCR), able to bind a molecular complex consisting of an antigenic 
peptide bound to a molecule of the MHC on the APC. The nature of 
peptides could be either cellular (endogenous antigens) or derived from 
extracellular proteins (exogenous antigens) after a proteolytic degradation 
process. The function of MHC molecule is to present peptides to T-cells; 
there are two class of MHC molecules: MHC I binds endogenous derived 
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peptides, while MHC II binds exogenous derived peptides. However, 
through a process defined cross-priming, also exogenous antigens could 
be presented in association with MHC I molecule on professional APCs. 
MHC II molecules are expressed only on certain cells, most of which are 
bone marrow derived cells, and are recognized by T CD4+ helper cells,  
while MHC I molecules are expressed virtually on all nucleated cells and 
are recognized by T CD8+ lymphocytes. The co-receptors CD4 and CD8 
bind non-polymorfic regions of MHC molecules, whereas the TCR interacts 
with both MHC and their bound peptide. 
Accordingly, when naïve T CD8+ and T CD4+ cells recognize tumor antigen 
presented in association with MHC I and MHC II molecules respectively, 
and when the essential costimulatory signals are provided, these cells 
become activated. 
Briefly, activated T CD4+ cells secrete cytokines that regulate activated T 
CD8+ cells, but cannot interact with cells that not express MHC II 
molecules; conversely T CD8+ cells can directly interact with MHC I 
expressing tumor cells and mediate the lyse of tumor cells after this 
recognition [Goedegebuure et al., 2002].  
1.2.5 Immunotherapeutic approaches in cancer 
On the basis of what was previously decribed, immunotherapy can be 
divided in three main categories, as exhaustively showed in a review of 
Rosemberg and colleagues [Rosenberg et al., 2008]: 
1) Non specific immunomodulation: includes the administration of rh IL-2  in 
order to activate endogenous reactive T-cells in vivo, causing regression of 
many human cancers [Morgan et al., 2006, Rosemberg et al., 1985]. The 
disadvantage of this treatment is the toxicity of the cytokine if administrated 
at high doses. Another non specific immunomodulation include the use of 
mAbs direct against the cytotoxic T-lymphocytes-associated 4 (CTLA4), a 
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cell surface inhibitory molecule; as in the case of rh IL-2, the best clinical 
responses are those of melanoma and RCC patients [Phan et al., 2003, 
Attia et al., 2005, Margolin et al., 2000].  
2) Active immunotherapy: includes cancer vaccines, that are based on 
immunizing cancer patients against their autologous cancers using either 
whole cells, peptides or a wide variety of immunizing vectors. This idea 
behind cancer vaccines is generally meant to boost the immune system to 
fight against the cancer just like vaccine to infection. Cancer vaccines are 
active immunotherapy because they triggering the patient’s immune system 
to respond. However, they could be divided in  preventive and therapeutic 
cancer vaccines. Although the concept of preventive vaccine is very 
intriguing, and there are some examples such as the vaccines against 
different genotypes of human papillomavirus, in order to prevent the tumor 
of uterine cervice, the most of cancer vaccine in clinical trials are 
therapeutic. The first therapeutic vaccine, approved in 2010 by the FDA, 
was called Provenge and its successful for prostate cancer [Brower et al., 
2010]. 
Cancer vaccines typically consist of a source of cancer-associated material 
(antigen), along with other components, such as adjuvants, to further 
increase the specific antitumor immune response. Few example of cancer 
vaccines include: tumor cell vaccines, antigen vaccines, DC vaccines (like 
Provenge), anti-idiotype vaccines, DNA vaccines, and vector-based 
vaccines [Mishra et al., 2013]. One of the main disadvantages of cancer 
vaccines is that, if the tumor cells mutate after chemotherapy or radiation 
treatment, changing the targets of the vaccine, they become ineffective. 
3) ACT: is also called passive immunotherapy and refers to antibodies, or 
more frequent other immune-system components that are made outside of 
the body, in laboratory, and administered to patients to provide immunity 
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against cancer, with no active immune stimulation that is conversely 
produced in patients by cancer vaccines.  
Usually, after the identification ex vivo of autologous or allogenic 
lymphocytes with antitumor activity, they are re-infused into cancer 
patients, often in association with growth factors to promote their expansion 
and survival in vivo. The advantages of this approach include the necessity 
to identify only a small number of anti-tumor specific T lymphocytes with the 
appropriate characteristics, since they can be expanded to large number ex 
vivo before treatments; in addition, through in vitro test, the exact 
population of interest, able to mediate cancer regression, could be easily 
identified and selected for expansion; another important advantage is that 
these cells can be activated in laboratory in absolute absence of 
endogenous inhibitory factors and thus can be induced to exhibit the 
required anti-tumor effector function [Rosenberg et al., 2008]. 
1.2.5.1 Adoptive cell therapy using tumor infiltrating lymphocyte (TIL)  
One of the possible ACT strategies is based on the finding in 1987 that T 
infiltrating lymphocytes (TIL) could be isolated from melanoma tumors and 
cultured in vitro in presence of rh IL-2. These cells exhibit MHC-restricted 
recognition of autologous melanoma [Muul et al., 1987]. It has been 
demonstrated that, improving culture methods, about 1011 TIL could be 
generate having a specific melanoma activity in 81% of 36 consecutive 
patients [Dudley et al., 2003]. The infusion of TIL grown from the resected 
nodules of metastatic melanoma patients represent the clearest successful 
example of ACT for the treatment of patients with metastatic solid cancer, 
even if the first effective of ACT was demonstrated in the clinical context of 
haematopoietic malignancy as reported by Rosemberg and colleagues in 
1988 [Rosenberg et al., 1988]. However, the main disadvantage of their 
clinical trial was the short persistence of the transferred cells in vivo. To 
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overlap this limit, a profound host lymphodepletion is necessary before cell 
transfer [Dudley et al., 2002 and 2005, Gattinoni et al., 2005]. Adverse 
effects in the lymphodepletion trial included opportunistic infections an the 
frequent induction of vitiligo and uveitis, presumably due to autoimmunity. 
Other clinical trials that used ACT based on TIL re-infusion were shown in a 
review of  June [June et al., 2007], in which also the different strategies are 
reported to augment ACT. These randomized clinical trials involved several 
kind of tumors, like gastric cancer [Kono et al., 2002], renal cancer [Figlin et 
al., 1999], lung cancer [Ratto et al., 1996], and still melanoma [Dreno et al., 
2002]. Several studies used as main antitumor cells not TIL, but CTLs 
derived from PB. Also in this case the best clinical result of this strategy is 
melanoma tumor: these cells were used to treat patients with refractory , 
metastatic melanoma and 8 of the 20 patients had minor, mixed or stable 
antitumor  immune responses [Yee et al., 2002]. It has been demonstrated 
in a previously work of Yee and coworker [Yee et al., 2000] that the infusion 
of autologous MART-1-specific T CD8+ cells in to a patients with metastatic 
melanoma resulted in T-cell infiltration in both the skin and tumor tissue. 
The destruction of the normal melanocytes and the outgrowth of MART-1  
negative tumor demonstrated both the in vivo efficacy of the infused T-cell 
population and the selection of tumor variant with loss of MART-1 
expression [Yee et al., 2000]. However, this problem can be overtaken 
infusing CTLs clones with multiple antigenic specificity. An additional tumor 
in which PB T-cell were activated in vitro and re-infused in patients is the 
hepatocellular carcinoma [Takayama et al., 2000].  
1.2.5.2 Adoptive cell therapy for cancer patients expressing viral 
antigen or alloantigens 
As mentioned before, ACT is an effective treatment for several 
haematopoietic malignancy. It clear that when the target antigen on a tumor 
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is foreign to the host, as the viral antigen or alloantigens, the avidity of T-
cell is more higher than in other situations and the destruction of tumors 
can be very large. In 1990 Kolb and colleagues have shown that the 
treatment of three relapsed chronic myeloid leukaemia patients with buffy 
coats cells from hematopoietic stem cell (HSC) bone marrow donor 
determined cytogenetic remission (Kolb et al., 1990). Also in patients with 
relapsed chronic myeloid leukaemia the infusion of donor lymphocytes 
could mediate molecular remission in 70-80% of cases, and in a minority  of 
patients with relapsed multiple myeloma, following treatment with allogenic 
HSC transplantation [Mackinnon et al., 1995]. 
The adoptive transfer of EBV-specific T-cell lines and CTLs for the therapy 
of EBV-induced lymphomas is perhaps the best demonstration of clinically 
efficacious of ACT [Heslop et al., 1997, O’Reilly et al., 1997]. These 
lymphomas express latent EBV antigens, including the immunodominant 
EBV nuclear antigens (EBNA) EBNA-3A, B and C, that are ideal targets for 
immunotherapy. The risk for patients received allogenic HSC transplants in 
combination with immunosoppressive drugs to avoid episodes of graft 
versus host diseases is the developing of post-trasplant lympoproliferative 
disease (PTLD). In a study of Rooney et al. it has been demonstrated that 
donor-derived EBV CTL lines infused in 60 patients with a high risk to 
develop PTLD established the onset of malignancy in none of them, 
compared with the 11,5% of historical controls [Rooney et al., 1995]. This 
strategy was used of for the treatment of 16 nasopharyngeal carcinoma 
patients at stage 4, refractory to conventional treatments and in 11 patients 
with Hodgkin disease. It was possible since poorly differentiated 
nasopharyngeal carcinoma and Hodgkin’s lymphoma express the EBV 
latent membrane proteins (LMP-1,2), as well as the EBV EBNA-1 antigen. 
The results of these studies have shown two complete remission and three 
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partial remission in the context of nasopharyngeal carcinoma and three 
objective responses in Hodgkin’s lymphoma patients [Comoli et al., 2005, 
Bollard et al., 2004]. 
These results underlined as the administration of an avid anti-tumor cell, 
targeting a highly expressed antigen can result in cancer regression. 
Strength of the effectiveness of ACT directed against EBV and allogenic 
antigens, as well as the prevention of Cytomegalovirus (CMV) infection in 
immunosuppressed patients after the infusion of CMV-reactive autologous 
T-cell lines [Riddell et al., 1991], researchers have begun to evaluate all 
these data in order to improve the ACT approaches for the treatment of 
solid tumor. 
1.2.5.3 Adoptive cell therapy using gene modified lymphocytes  
The evidences that TIL with high avidity for tumor antigens could be 
generated essentially starting from only melanoma specimens, and the 
need to produce antitumor T-cells with broad reactivity against shared 
cancer-associated antigens expressed on different kind of tumors, have 
done the groundwork for the introducing of gene modified lymphocytes in 
ACT. This strategy is very useful also to try to ride over the mechanisms of 
immune evasion that mitigate the tumor-directed T-cell reactivity.  
Genetic modification of T-cells can be divided in such groups: one of the 
most important is represented by the genetically modified T-cells to allow 
them to recognize antigens expressed by tumor cells that could be done 
inducing expression of constitutive androstane (CAR) receptors that 
recognize tumors through single-chian variable fragments (scFv) isolated 
from specific antibodies [Eshhar et al., 1993] and inducing gene 
modification with α and β TCR chains cloned from TAA-specific T-cell 
clones with high antigen avidity [Schumacher, 2002] 
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Other genetic modifications were carried out to improve T-cell proliferation 
and survival: these includes genetically modification of T-cells with retroviral 
vectors encoding IL-2 or Interleukin-15 (IL-15) to produce cells which are 
cytokine self-sufficient and self-sustaining [Quintarelli et al., 2007, Liu et al., 
2001, Hsu et al., 2005], preventing in this way also the common side effects 
of high doses of rh IL-2; Quintarelli and colleagues have shown that these 
genetically modified T-cells had enhanced persistence and superior anti-
tumor activity in vivo compared to the unmodified cells [Quintarelli et al., 
2007]. Since T-cell proliferation requires continued antigenic stimulation, 
either via direct interaction with tumor cells or through professional APCs 
that cross present tumor antigens, and since many tumors lack expression 
of co-stimulatory molecules, such as CD80 and CD86, could be important 
to force the expression of co-stimulatory ligands [Stephan et al., 2007]. A 
way to increase the survival of T-cells is represented by their trasduction 
with anti-apoptotic genes, such as B cell lymphoma gene-2 (Bcl-2) and B 
cell lymphoma gene-extra-large (Bcl-xL) [Charo et al., 2005]. In addition, 
strategies to make antigen specific CTLs resistant to the effects of 
immunosuppressive drugs, in order to prevent the onset of virus-associated 
complication such as EBV-post transplant lymphoma [Paya et al., 1999], 
have been recently developed using the small interference RNA (siRNA) 
technology [De Angelis et al., 2009, Brein et al., 2009]. 
It is important to be successful in counteract the immunosuppressive tumor 
microenvironment; since the main tumor evasion strategy is the local 
secretion of TGF-β, researcher have developed, in murine models, a way to 
modify CTLs, supporting their expression of dominant negative TGF-β  
receptor type II: the results are encouraging because these modified CTLs 
are resistant to the antiproliferative effect of TGF- β both in vitro and in vivo 
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[Bollard et al., 2002]; a clinical trial based on this strategy is on going for the 
treatment of patients with relapsed/refractory Hodgkin’s lymphoma. 
Some genetic modifications were designed to redirect T-cell migration in 
vivo, because tumors can generate chemokine milieu that significantly 
modifies the trafficking of Th1, Th2 cells and T regs [Dilloo et al., 1996, Gao 
et al., 2008], unbalancing dangerously to the last two.  
Finally, other modifications were done to reduce the inevitable risk of 
toxicity and of unwanted proliferation of the genetically modified produced 
T-cells. To allow the rapid and complete elimination of infused cells, several 
groups have evaluated safety switches or suicide genes, which can be 
triggered when toxicity occur [Ciceri et al., 2009, Traversari et al., 2007, 
Thomis et al., 2001, Straathof et al., 2005 (b), Tey et al., 2007].   
1.3 Immunotherapy in CRC 
Nowadays immunotherapy for CRC remains only and experimental option, 
although some clinical trials of cancer immunotherapy have demonstrated a 
potential benefit for these patients.  
As mentioned previously, immunotherapy has the potential to eradicate 
cancer by eliciting immune responses through the recognition of specific 
antigens on tumor cells. However, the lack of antigens that are effectively 
tumor-specific limits the development of immunotherapy. This consideration 
is especially true for CRC, that is a very poorly immunogenic tumor.  
1.3.1 The tumor antigens of CRC  
For CRC patients, the evidence that tumor cells are able to induce a tumor-
specific T-cell response in the autologous setting is still scarce, even if few 
immunological studies have been performed [Dalerba et al., 2003]. 
On the bases of melanoma immunotherapeutic results, the first 
investigations in CRC were done using TIL, but due to difficulties in 
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obtaining stable CRC cell lines, encountered also in our project, only few in 
vitro studies have demonstrated the human leukocyte (HLA)-restricted anti-
tumor reactivity of TIL obtained from colorectal carcinoma lesions. This is 
one of the reasons because few molecular defined TAA has been reported 
for CRC. 
Through this approach, Saeterdal and coworkers [Saeterdal et al., 2001] 
have been identified a peptide derived from a frameshift mutation of the 
transforming growth factor β receptor type II (TGFβRII) and presented by 
HLA-DR, that is able to be recognized by TIL purified from CRC lesions and 
expanded in vitro by rh IL-2. Since the mutated form of TGFβRII is 
detectable only in tumors, and its inactivation occurs in 90% of 
microsatellite instability (MSI) CRC, it could be considered as a TSA and 
could be a good candidates for immunotherapy, also because TGFβRII 
gene appears to play an active role in tumorigenesis. After that, other two 
peptides were identified with this strategy: squamous cell carcinoma 
antigen recognized by T-cell 3 (SART-3) and cyclophilin B (CycB) [Ito et al., 
2001, Tamura et al., 1999, Yang et al., 1999, Myagi et al., 2001]. The first 
protein is more promising than the second, that is ubiquitously expressed in 
normal as well as in cancer cells; in fact SART-3 was used, in combination 
with different doses of SART-3 derivate peptides, for phase I clinical trial 
and results showed a significant increase in the precursor frequency of 
peptide-specific T-cells in peripheral blood mononuclear cells (PBMCs) 
after three cycles of vaccination, even if without objective clinical 
responses. 
Since a specific antitumor T-cell activity is not only local (detected in tumor 
site) but also systemic, different strategies, based on a reverse 
immunological approach using the properties of DCs, that could be load 
also with a tumor lysates and so without the need to establish molecular 
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defined antigens, have been developed. Bremers and colleagues [Bremers 
et al., 2000] showed that tumor specific T-cells, generated after the PBMC 
stimulation with DCs loaded with tumor lysate, are directed against TAA 
epitopes derived either from differentiation or from TSA. Consequently the 
presence of a relative high precursors frequency of TAA-specific T-cells in 
PB of the immunized patients, and an in vivo systemic immunisation, 
occurred during the natural course of disease, could be hypothesised 
[Dalerba et al., 2003].  
Through this second approach several epitopes, able to induce a 
spontaneous systemic immunity in CRC, have been molecularly identified. 
Among them, an important role is played by CEA, the most old studied 
molecule [Gold et al., 1965], EpCAM and Her-2/neu proteins, belonging to 
the category of differentiation antigens. The first two are cell surphace 
adhesion molecules expressed by more than 90% of CRC, while Her-2/neu 
is an epithelial growth factor receptor over-expressed in a subset of CRC. 
In particularly, it has been demonstrated that CEA promote the aggregation 
of CRC cells and also may facilitate metastasis by acting as L-selectin and 
E-selectin ligands [Thomas et al., 2008]. It is expressed by several adult 
tissues and can be found at low levels in healthy adult blood [Benchimol 
1989, Thomas 2008], but it is over-expressed by adenocarcinomas of the 
colon, rectum, breast and lung and can be detected at high levels in the 
serum of these patients [Hammarstrom, 1999]. These features make CEA 
as diagnostic marker, but its expression also in normal tissues limits the 
specific immune responses elicited by cancer vaccines [Xiang et al., 2013]. 
Another potential TAA expressed by CRC is p56lck, a tyrosine kinase 
member of the src family, essential for T-cell development and function, 
potentially involved in the process of neoplastic transformation and 
progression [McCracken et al., 1997]. Similarly with the data on anti-CEA, 
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anti-EpCAMand anti-Her-2/neu T-cells, CTLs frequency against HLA-
restricted p56lck peptides reached a detectable levels only in advanced CRC 
stages [Harashima et al., 2001, Imai et al., 2001]. 
Two other potential antigens for CRC immunotherapy are mucin 1 (MUC1) 
and Guanylyl cyclase C (GCC). MUC1 is a transmembrane glycoprotein 
founded on the apical surface of secretory  epithelial cells [Hollingsworth et 
al., 2004], able to bind pathogens to limit bacterial invasion but also to 
regulate cell motility and survival [Linden et al., 2009; Singh et al., 2006]. It 
could be over-expressed in several types of adenocarcinoma, and 
specifically in CRC, could be also subject to an abnormal glycosylation, 
events that are associated with a poor prognosis prognosis by regulating 
tumor-promoting signaling pathways such as β-catenin and k-ras [Ajioka et 
al., 1997; Singh et al.,  2006]. Guanilate cyclase 2 C (GUCY2C) is a 
receptor for the endogenous hormones guanylin and uroguanylin and 
exogenous bacterial heat-stable enterotoxin [Lucas et al., 2000]. It is 
primarily expressed on the apical surfaces of intestinal epithelial cells, 
regulating numerous physiological and pathophysiological processes [Kim 
et al., 2013] and it has been previously reported that GUCY2C expression 
persists through all stages of colorectal tumorigenesis from premalignant 
polyps to distant CRC metastases [Cagir et al., 1999; Carrithers et al., 
1996; Waldman et al., 1998]. Since its expression it has been shown to be 
maintained in the 95% of metastatic CRC [Carrithers et al., 1996, Schulz et 
al., 2006], GUCY2C could be used as biomarker for metastatic CRC, as 
confirmed by several retrospective and prospective clinical trials [Cagir et 
al., 1999; Carrithers et al., 1996, Waldman et al., 2009]. 
Other antigens, such as Sialyl-Tn, surviving, as well as mutated antigens, 
including p53 and k-ras have been studied in CRC, though without great 
success. 
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1.3.2 Active immunotherapy in CRC 
As regards the specific case of CRC, although the concept of a 
preventative vaccine is appealing, current CRC vaccines are applied to 
activate the immune system to destroy tumours once they are detectable 
and, therefore, are considered ‘therapeutic’. As mentioned previously, the 
vaccines could be divided in six main categories; some of these have been 
clearly discussed by Xiang and colleagues [Xiang et al., 2013], and those 
used for CRC are reported below: 
1) Autologous tumor cell vaccines: the preparation of these vaccines start 
from tumor cells isolated from patients, engineered into a vaccine ex vivo, 
and re-administered to the patients. It is not required the definition of 
specific tumor antigens since whole autologous tumor cells comprise all 
tumor antigens, but a significant disadvantage to this approach is the 
difficult to generate a “universal” vaccine applicable to each patient. In 
addition, the immune response to these vaccines is very low, probably due 
to a lacking representation of specific tumor antigens in the vaccine 
[Lokhov et al., 2010]; in fact only a small proportion of the proteins 
expressed by a cancer cell are specific to tumor cells, while the vast 
majority of antigens in the vaccine are shared among normal cells [Xiang et 
al., 2013]. Nowadays, the results of this approach has not clinical benefit to 
patients. However, there are some clinical trials based on the use of whole 
tumor cell lysates in association with bacillus Calmette-Guerìn (BCG) or 
bacterial cell wall products as adjuvants, but the results were not 
statistically significant between vaccine and negative control group [Gray et 
al., 1989]. OncoVAX (Vaccinogen, Inc.) is a personalized antitumor vaccine 
using irradiated non-tumorigenic autologous tumor cells with BCG [Uyl-De 
Groot et al., 2005]. It has been demonstrated that in stage II of CRC this 
vaccine had a better outcome on survival and disease-free survival in 
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vaccinated patients than controls, even if the recurrence events are 
frequent [Harris et al., 2001]. 
Another strategy of CRC tumor vaccine uses autologous, virus-infected 
(such as with Newcastle disease virus), irradiated tumor cells, without BCG 
because the virus infection provides an adjuvant effect, but in this case 
patients had no significant improvement in overall survival, disease-free 
survival or metastases-free survival, even if subgroups analysis suggested 
some benefit from this vaccine [Schulze et al., 2009]. 
2) Peptide vaccines: These vaccines are based on the identification and 
synthesis of epitopes, which can lead an anti-tumor antigen specific 
immune response. Also these vaccines are often associated with 
adjuvants. The main advantages of this vaccine’s category are the easy 
production and the low cost [Parmiani et al., 2002], and a low autoimmunity 
risk since they are produced from truly tumor specific antigens, like mutate 
peptides. Conversely, their major disadvantages are the cancer recurrence 
due to the antigenic escape, the poor immunogenicity and the HLA-
restriction, that limit these vaccines to specific HLA-haplotypes [Bartnik et 
al., 2013, Parmiani et al., 2002]. In a study of Okuno and co-worker [Okuno 
et al., 2011] was analysed the clinical response of 21 CRC patients, after a 
peptide vaccination with two TSA: ring finger protein 43 (RNF43), and 
translocase of outer mitochondrial membrane 34 (TOMM34), whose 
expressions were up-regulated in about 80% of CRC specimens compared 
to normal mucosa [Shimokawa et al., 2006, Yagyu et al., 2004]; results 
showed that 38% and of 57% patients had a positive CTLs response 
against both peptides and one of them respectively, while one patient did 
not respond [Okuno et al., 2011]. Other complete examples of peptide 
vaccines could be found in a review of Merika et al. [Merika et al., 2010]. 
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However, future phase II and III studies are needed to defined the real 
efficacy of these approaches  compared to established treatments for CRC. 
3) DC vaccines: DCs can be collected from patients, pulsed with tumor 
epitopes, matured ex vivo, and transferred back into patients as cancer 
vaccine to induce antitumor activity. As mentioned before, there are several 
ways to load DCs with tumor antigen, and these methods include: pulsing 
DCs with peptides derived by tumor antigens [Mayordomo et al., 1995], or 
tumor cell lysates [Berard et al., 2000] and physically fused DCs with tumor 
cells [Gong et al., 1997]. In addition, DCs may be also transduced with non-
replication recombinant viral vectors, or transfected with RNA or, less 
commonly, plasmid vectors encoding TAA [Bonaccorsi et al., 2013]. 
Different clinical trials have been used this vaccination strategy in CRC. For 
example, tumor cell lysate pulsed DC is able to induce an antitumor T-cell 
response both in vitro and in vivo [Wu et al., 2010, Tamir et al., 2007]. A 
phase II study has reported that 20 advanced CRC patients, treated with 
autologous DCs pulsed with allogenic tumor cell lysate contained CTA, 
showing median survival of 5,3 months with stable disease in 24% patients 
and without toxic effects [Burgdorf et al., 2008]. Viral vectors have also 
been used to load DCs with tumor antigens or trasduce them with tumor 
specific genes such as CD40L [Liu et al., 2002], often in association with 
co-stimulatory molecules or cytokines, in order to enhance the T-cell 
response. Since CEA is the most widely used antigen for loading DCs 
[Morse et al., 1999], a lot of vaccination’s clinical trials are based on this 
strategy in CRC [Itoh et al., 2002, Morse et al., 2005, Liu et al., 2004, Fong 
et al., 2001, Babatz et al., 2006]. Other DC vaccines have investigated the 
responses to multiple TAAs, loading autologous DCs with peptides derived 
of multiple TAA to determine priming of antigen specific T CD8+ cells and 
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whether responses to all the antigens included in the vaccine can be raised 
[Hasegawa et al., 1998, Kavanagh et al., 2007].  
The results of these study are encouraging in much cases, but most 
researches are necessary in order to improve T-cell migration and to 
facilitate transfer of activated CTLs to tumor sites, since at now, objective 
clinical responses to these vaccinations in CRC remain low. 
4) DNA vaccines: a DNA vaccine is naked plasmid DNA that induces 
expression of specific antigens upon delivery to mammalian cells. The 
action mechanisms of these vaccines to activate immune system rely 
several processes like the interaction between the un-methylated CpG 
motifs of DNA plasmids derived from bacteria, and the Toll-like Receptor 9 
(TLR9) on APCs, leading to DCs maturation [Hammiet et al., 2000]. The 
presentation of plasmid DNA can occur in a direct or indirect manner: 
during direct presentation plasmid DNA is delivered directly into DCs, 
resulting in antigen expression and presentation by the DCs. During the 
indirect presentation, plasmid is delivered by parenchymal cells, which 
express the antigens [Xiang et al., 2013]; after that, the antigen is acquired 
by DCs that lead the cross presentation mechanism to naïve T-cells in 
lymph nodes to induce adaptive immunity. However, at now no DNA 
vaccines for human cancer have been approved. An example for CRC is a 
phase I clinical study based on a DNA vaccine expressing CEA and 
hepatitis B surface antigen; in this trial, even if immune response was 
observed in 23% of metastatic CRC patients, no objective clinical 
responses were observed [Conry et al., 2002]. 
5)Viral-vector vaccines: viral vectors, that include mainly recombinant 
poxviruses, lentiviruses, retroviruses, adenovirus, could be engineered to 
express tumor antigens and the natural immunogenicity of viral vectors acts 
as an adjuvant to help boost tumor antigen-specific immune response; in 
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spite of the disadvantages based on potential pathogenesis and mutational 
ability, several viral-vector vaccines have been proposed for CRC in clinical 
trials. It is important to clarify that the majority of CEA vaccines use viruses 
such as ALVAC for its delivery to tissue, often in association with co-
stimulatory molecules [Horig et al., 2000, von Mehren et al., 2000], but the 
objective clinical responses were disappointing. ALVAC has also been 
used as a vector to deliver EPCAM, an important mediator of cell-cell 
interaction and a factor involved in the growth, differentiation and 
organization within tissues. EPCAM functions are similar to KSA antigen, a 
human pancarcinoma antigen highly expressed in colon tumors. The 
results of Ullenhag and colleagues shown a strong IFN-γ immune response 
after this kind of vaccination [Ullenhag et al., 2003]. Another viral-vector 
vaccine is directed against the antigen MUC-1 and it seems to be promising 
in patients with inflammatory bowel disease (IBD), in which a strong 
immune response against this antigen has been observed. It will be 
important to clarify if this response can reverse the premalignant 
microenvironment, typical of these patients, and prevent the likely 
development of CRC. 
6)Anti-idiotypic antibodies vaccines: it was demonstrated that mAbs can be 
used also as vaccine, exploiting the so-called Jerne’s idiotypic network 
[Foon et al., 1999, Herlyn et al., 1996, Maxwell-Armstrong et al., 1998]. 
According to the idiotypic network hypothesis, a mAb directed against one 
specific TAA, can be used to immunise animals and induce the production 
of polyclonal antibodies directed against its variable region [Dalerba et al., 
2003]. These antibodies could be used in turn as vaccines in order to 
induce a second round of anti-idiotypic antibodies that should be similar to 
the first antibodies, recognizing the original TAA on the patient’s cancer 
cells. On the basis of this strategy, several clinical trials for CRC have been 
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started using anti-idiotypic antibodies mimicking the antigen CEA, Ep-CAM 
or CD55 (gp72 antigen). These antibodies induced an immunization in 
cancer patients, but with low clinical efficacy and their overall survival was 
not improved, neither with anti-idiotypic antibody against CEA [Foon et al., 
1997], nor Ep-CAM [Herlyn et al., 1996, Samonigg et al., 1999], nor CD55 
[Denton et al., 1994, Maxwell-Armstrong et al., 1998]. These antibodies 
with low clinical activity as vaccines are ongoing as adjuvant setting in other 
active immunization strategies [Durrant et al., 2000, Birebent et al., 2001].       
 1.3.3 Adoptive immunotherapy in CRC 
Passive immunotherapy is the therapeutic administration to the patient of 
live cellular immune effectors, usually after in vitro expansion, activation 
and/or gene modification, in order to improve their anti-tumor activity. One 
form of this therapy is ACT. It is known that the majority of ACTs focused 
on T-cell therapy, due to the highly specific nature and potent killing ability 
of T-cells [Xiang et al., 2013]. One of the main advantages of this approach 
is that, with an ex vivo reprogramming and activation, T-cells may 
overcome some mechanisms of self-tolerance, which inhibit T-cell 
activation in vivo [Restifo et al., 2012]. Indeed, it has been demonstrated 
that the administration of large numbers of tumor specific T-cells may 
induce cancer regression. As described previously, disadvantages of this 
approach are the potential lack of immune memory, poor persistence of 
adoptive T-cells in vivo, long time (from 4 to 16 weeks) to produce these 
cells in research’s laboratory, high costs, as well as the risk of severe side 
effects.  
Basing on melanoma immunotherapeutic strategies, the primary 
approaches for ACT in CRC have used TIL, or genetically engineered T-
cells, since it has been demonstrated that some tumors posses tumor-
antigen-specific T-cells within tumor microenvironment [Dudley et al., 
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2002], but it is known that these cells are suppressed or dysfunctional such 
that cancer cells overwhelm the response [Whiteside, 2006].  
It should be emphasized that although melanoma is unique in its ability to 
naturally result in the generation of anti-tumor T-cells in vivo, there does not 
appear to be any difference in the susceptibility of different cancer types to 
the anti-tumor activity of lymphocytes. Thus principles that are being 
learned about the effectiveness of ACT in patients with melanoma can be 
of value in applying ACT therapy to patients with other cancer types. 
Unfortunately, it seems that the use of TILs, which can be re-stimulated ex 
vivo to revert their unresponsive state, is limited to melanoma patients due 
to a higher immunogenicity of melanoma in comparison to other cancers.  
Alternatively, the generation of genetically engineered T-cells expressing 
receptors, having specific affinity for tumor antigens could facilitate the 
targeting of virtually any tumor type. Indeed, T-cells engineered to express 
high avidity TCRs target tumors of various histological origins [Xiang et al., 
2013]. The disadvantage of this approach is the TCR limitation to patients 
with the corresponding MHC haplotype. Conversely, the use of CARs, 
which express a scFv derived from a tumor antigen-recognizing mAb, fused 
to intracellular T-cell signaling domains, can be used universally across all 
patients since CARs target native antigens on the surface of tumors without 
MHC restriction [Xiang et al., 2013]. In a study of Parkhurst and colleagues 
[Parkhurst et al., 2011] a phase I trial was done in three metastatic CRC 
patients using T-cells engineered to express a high avidity CEA-specific 
murine TCR; although all patients showed a decreased CEA serum levels, 
severe side effect was observed: all three patients developed a severe 
transient inflammatory colitis. In another clinical trial of Morgan an co-
workers [Morgan et al., 2010], one metastatic CRC patient was treated with 
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Her2-specific CAR T-cells, but also in this case adversely effects were 
observed. 
However, also previous studies, in which adoptive immunotherapy for CRC 
has been attempted with IFN-γ activated macrophages [Lopez et al., 1992, 
Hennemann et al., 1995, Eymard et al., 1996], and with IL-2-activated 
lymphocyte effectors, such as TIL or lymphokine activated killer cells (LAK),  
showed no substantial clinical efficacy [Rosenberg et al., 1992, Hawkins et 
al., 1994, Dillman et al., 1991, Fabbri et al., 2000], probably due to the low 
frequency of anti-tumor T-cells in lymphocyte preparation [Parmiani, 1990] 
and to the escape of T-cell response by tumor cells due to  HLA-loss 
variants [Marincola et al., 2000].  
Up to now, ACT has failed to demonstrate safety and efficacy in CRC 
patients, so future studies will have to identify which are the mechanisms 
that can selectively eliminate cancer cells, without damage normal tissues, 
and which are the best strategies to produce a great number of activated 
and tumor specific T-cells.  
Among the strategies employed for in vitro inducing an adequate activation 
and expansion of tumor-reactive T-cells, an actively investigated approach 
involve the use of DCs pulsed with whole tumor cell preparations, with 
either tumor extracts or apoptotic tumor cells, to cross-prime CTLs [Schnurr 
et al, 2002; Kurokawa et al, 2001]. 
A recently described procedure for generating in vitro large numbers of 
anti-tumor HLA restricted CTLs, alternative to the exploitation of TIL, 
involves stimulating patient’s CD8+ -enriched PBMCs with DCs pulsed with 
apoptotic solid tumor cells as a source of tumor antigens [Montagna et al, 
2004]. The advantage of this experimental approach, utilizing whole tumor 
cells to stimulate cultures, is that it requires neither the definition of specific 
tumor antigens, nor the availability of TIL, thus being potentially applicable 
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in the generation of anti-tumor CTLs against a wide variety of solid tumors, 
and so even against CRC, for which a successful ACT approach was still 
not found. 
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2. AIM OF THE STUDY 
 
 
42 
 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers 
worldwide. More than 1 million people worldwide are diagnosed with CRC 
each year, and a staggering 0.5 million die of the disease in the same time 
period. The finding of new therapeutic strategies to treat CRC patients 
could be useful to improve these discouraging data. 
The adoptive cellular therapy (ACT), based on the transfer of ex-vivo 
tumor-induced T cytotoxic lymphocytes (CTLs) provides a promising 
approach in cancer immunotherapy.  
The ex vivo production of T-lymphocytes with specific reactivity towards the 
tumor cells is a prerequisite for designing an effective immunotherapy, 
aimed at controlling the tumor growth and overcoming the immune evasion 
mechanisms of the tumor. 
It is well known that the success of ACT with ex vivo expanded anti-tumor 
CTLs depends on the number, features and abilities of the administered 
cells. The activation of CTLs is usually mediated by autologous dendritic 
cells (DCs) pulsed with either tumor extracts or apoptotic tumor cells, to 
cross-prime the cells. This strategy has been successfully adopted in 
metastatic melanoma, and in other selected solid tumors, but not in CRC, 
for the difficulties in isolating tumor infiltrating lymphocytes (TILs), in 
identifying specific or associated tumor antigens, poorly expressed in CRC, 
and in amplifying a sufficient quantity of autologous tumor-reactive T-cells, 
capable of preserving their cytotoxic capacity after expansion for 
therapeutic use.  
The main aim of the project was the extension of the ACT approach to the 
treatment of CRC, by retrieving the tumor-reactive T-cells from the 
peripheral blood mononuclear cells (PBMCs) of the patients affected by 
CRC. In order to fulfil this aim, primary colon cancer cell lines were 
established for CRC biopsies, and induced to enter the apoptosis process. 
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Then, the tumor cells were cocultured in presence of autologous CTLs, 
generated by stimulation of patients’ CD8+ enriched PBMCs, and of DCs.  
The improvement of the ACT strategy could determine the development of 
a novel tumor-specific therapeutic approach in CRC treatment, 
characterized by increased efficacy and decreased toxicity. 
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3. MATERIALS AND METHODS 
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3.1 CRC patients  enrollment  
Starting from Local Ethical Committee permission and the signature of the 
informed consent by patients, 78 subjects affected by CRC and undergoing 
surgery were enrolled. Thirty-nine CRC patients specimens were obtained 
from San Giuseppe Hospital (Milan), and 39 from “Città Studi” Clinical 
Institute (Milan). 
The enrollment of the patients was performed fulfilling the following 
inclusion criteria:  
- Patients ≥18 years old. 
- Patients with diagnosis of CRC. 
- Possibility to obtain a fresh tumor specimen from the patient. 
- Possibility to collect PB samples from the patient. 
Exclusion criteria comprise: 
- Absence of signed informed consent. 
- Inadeguacy of samples. 
 
SEX N (%) MEAN AGE (range) 
Female 43/78 (55,1%) 75,1 (46-87) 
Male 35/78 (44,9%) 70,1 (53-92) 
Table 1: Case Study 
 
3.2 Primary tumor cell lines  
Tumor samples were obtained at surgery, and immediately placed in sterile 
RPMI 1640 medium (Euroclone) added with 20% of Fetal Bovine Serum 
(FBS) (South America, Euroclone), 1X L-Glutamine (Euroclone), 1X 
penicillin/streptomycin (Euroclone), 50 µg/mL gentamicin (Euroclone), and 
with 0,25 µg/mL Amphotericin B (Euroclone) to avoid infectious agents 
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contaminations. The medium with colon biopsy must be rapidly delivered in 
to the laboratory to be processed (Figure 4). 
 
        
Fig.4: Colon biopsy (2cm x 2cm). 
After removing fat and necrotic tissue, tumor biopsy was placed in 
GentleMacs Tube (Miltenyi Biotec) and dissociated to a single-cell 
suspension using the Gentlemacs® dissociator (Miltenyi Biotec), in 
accordance to manufacturer's practice. The cell suspension was then 
filtered using a Cell Strainer (70μm) (Beckon Dikinson) in order to keep out 
the tumor residues.   
At first, tumor cells were seeded in 24-well at 0.5-1x106 cell/mL in 
transporting medium described before, and cultured at 37°C-5% CO2 over a 
2-3 weeks period; later RPMI medium was replaced by CellGro (CellGenix), 
also supplemented with 20% FBS (Euroclone) and with the same amount 
of antibiotics and antimycotics, to improve the obtainment of primary tumor 
cell lines. Anyhow, upon tissue/cell adherence, medium volume was 
gradually increased over 3-5 days, and the changed weekly until a 
substantial outgrowth of cells was observed [Montagna et al., 2004]. When 
tumor cells cover at least 70% of growth surface they were washed with 
phosphate buffered saline (PBS) (Euroclone), tripsinized and sub-cultured 
by 1:2 or 1:3 split ratio; tripsin (0,05%, Euroclone) is also useful to remove 
any fibroblast contamination from culture. Early-passage, rather than long 
term passage tumor cells were used to minimize the possibility of 
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modifications of primary characteristics as a consequence of extensive re-
culturing (Freshney 1985). Tumor cell lines, after morphological-
phenotypical analysis, were cryopreserved  in freezing medium, composed 
by 90% FBS (Euroclone)  and 10% Dimethyl sulfoxide (DMSO) 
(Euroclone), until their subsequent use. 
3.3 Peripheral blood samples  
When possible, about 100 ml of PB was taken from CRC patients, who 
underwent surgery for the removal of tumor, using sterile violet vacutainer 
tubes containing the anticoagulant ethylenediaminetetraacetic acid (EDTA). 
After a blood 1:2 dilution in PBS (Euroclone), PBMCs were isolated by 
Ficoll-PaqueTM PLUS (GE Healthcare) density gradient centrifugation. 
Differential migration during centrifugation results in the separation of cell 
types into different layers (Figure 5).         
             
                                           
Fig.5: Sample layering before and after Ficoll density gradient centrifugation.     
         
The bottom layer contains Ficoll-aggregated red blood cells (RBC). 
Immediately above, there is a diffuse layer containing mostly granulocytes 
and unbound Ficoll. Due to a slightly lower density, the lymphocytes 
(including the monocytic PBMC fraction) sediment at the interface between 
the Ficoll and uppermost plasma/platelet layer. PBMCs are removed from 
the interface and subjected to multiple washes in PBS to remove any 
residual Ficoll. Isolated cells were stained with 0,4% Trypan blue 
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(Euroclone), and counted in a Burker chamber under a light microscope. 
On the basis of cellular count, 4-5 aliquotes of PBMCs were cryopreserved 
in freezing medium for the setup of future experiments, while PBMCs who 
remained were used immediately for the subsequent manipulations.  
3.3.1 Cells isolation through magnetic labeling 
Cells labelling with magnetic beads is one of the most recent approaches 
used to isolate the cellsm of interest starting from a set of cell populations. 
As reported by Miltenyi Biotech, MACS® Separation Columns (MS) were 
developed for the fast separation of any cell type labeled with MicroBeads, 
human (Miltenyi Biotech). The cells obtained, ready to use for experimental 
design, showed excellent yields and purities, preserving their functionality. 
The matrix of the MS columns is composed of ferromagnetic spheres, 
which are covered with a cell-friendly coating allowing fast and gentle 
separation of cells. When placed in the magnetic field of a MiniMACSTM 
Separator (Miltenyi Biotech), the spheres amplify the magnetic field by 
10,000-fold, thus inducing a high gradient within the column. This is crucial 
for isolation of cells which are only minimally labeled with MicroBeads, 
human (Miltenyi Biotech), leaving enough epitopes free for concurrent 
antibody staining. The space between the spheres is several times larger 
than primary and most cultured cells. This allows the cells to freely flow 
through the column. Magnetically labeled cells are held in suspension 
within the column and do not actually “bind” the column matrix. This 
suspension minimizes stress on the cells and allows for efficient sterile 
washing by avoiding cell aggregation. This methodology was choose to 
obtain an efficient and high purity isolation of three cell populations: CD8+ 
T-cells, CD14+ monocytes, and CD4+ T-cells. All those cell populations 
were isolated by a positive immunomagnetic selection. 
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3.3.1.1. T CD8+ lymphocytes isolation 
CD8+ T-lymphocytes were isolated from PBMC via positive 
immunomagnetic selection. PBMC were centrifugated at 300 x g for 10 
minutes; then, supernatant was completely removed. Cell pellet was 
resuspended in sterile, cold, AutoMACSTM Running Buffer (MACS buffer, 
Miltenyi Biotech). Specifically, cells were resuspended in 80 μL of MACS 
buffer with the addition of 20 μL CD8+ microbeads (Miltenyi Biotech) per 107 
total PBMCs; cells were mixed well and incubated on ice for 15 minutes. 
Cells were then washed using 1-2 mL of MACS buffer and resuspended in 
500 μL of the same buffer. The labelled preparation was passed through a 
MS separation columns (Miltenyi Biotech) attached to magnetic field 
(MACS MULTI STAND, Miltenyi Biotech) and the flow-through cells 
recovered in a falcon as negative fraction and used for subsequent T-cell 
magnetic labelling. Loading columns were washed three times using 500 
μL of MACS buffer following the manufacture’s instructions. To elute the 
fraction containing the magnetically labelled cells, 1mL of MACS buffer was 
added after the column was removed from the magnetic field and 
immediately flushed out using a sterile plunger (Miltenyi Biotech). The 
positive cell fraction was stained with 0,4% Trypan blue (Euroclone), 
counted in a Burker chamber under a light microscope, and evaluated by 
flow cytometry. The isolated T CD8+ cells were than cryopreserved for the 
subsequent experiments.  
3.3.1.2. T CD4+ lymphocytes isolation 
The T CD4+ cells isolation started from the negative fraction of the cell type 
previously isolated. The negative fraction was centrifuged, and the cell 
pellet was resuspended in MACS buffer as reported above. The isolation 
protocol was the same for all the cell population; the only specific reagent 
for each separation is represented by magnetic micro-beads (CD4+ 
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Microbeads, human, Miltenyi Biotech), that, in this case, are able to bind 
only T CD4+ cells. Also this cell fraction was stained with 0,4% Trypan blue 
(Euroclone), counted in a Burker chamber under a light microscope, and 
evaluated by flow cytometry. The isolated T CD4+ cells were than 
cryopreserved for the subsequent experiments. 
3.3.1.3. CD14+ monocytes isolation 
The negative fraction recovered from T CD4+ cells isolation was centrifuged 
in order to proceed with the CD14+ microbeads (CD14+ Microbeads, 
human, Miltenyi Biotech) labelling for monocytes isolation. The isolated 
CD14+ cells were immediately cultured to obtain immature DCs. 
3.4 Generation of immature Dendritic cells 
CD14+ monocytes were counted and plated in 6 wells at concentration of 
600.000 cells/mL in a final volume of 2,5 mL, ready to became, under the 
appropriate stimuli, iDCs. Before starting stimulation, CD14+ cells were 
allowed to adhere in RPMI 1640 (Euroclone)  medium containing 3% of 
FBS (Euroclone) from one to two hours at 37°C, 5% CO2 humidity. After 
this incubation, the non-adherent cell populations were throw away with 
PBS (Euroclone) washings. The adherent monocytes were cultured in 
RPMI 1640 (Euroclone) with 10% FBS (Euroclone), in presence of 
recombinant human Interleukin 4 (rh IL-4) (500U/mL) (Immuno Tools) and 
recombinant human Granulocyte-Macrophage Colony-Stimulating Factor 
(rh GM-CSF) (800-1000U/mL) (Immuno Tools). The day following, the cells 
were checked at light microscopy to eventually identify some contaminant 
lymphocytes. If a contamination of lymphocytes was observed in monocyte-
DC culture, the medium must be centrifuge, the pellet discarded and the 
medium with cytokines, added again to the culture. After 2/3 days, half 
culture medium was removed and replaced with fresh medium containing 
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the same starting amount of cytokines. At day 6 or 7 of culture, iDCs were 
counted under a light microscope and subjected to flow cytometry.  
3.5 Ultraviolet B (UV-B) irradiation  
During the course of experiments it was necessary to perform a UV-B 
irradiation of different cell populations. The cells irradiation is a 
methodology to drive the cell population of interest in a process of 
programmed cell death, know as apoptosis. The apoptosis of several cell 
populations (primary tumor cell line, T CD4+ lymphocytes and autologous 
PBMCs) was evaluated by flow cytometry, using Annexin V and Propidium 
ioduro (PI). One of the earliest features of apoptosis is a morphological 
change in the cell plasma membrane. This involves the translocation of the 
membrane phospholipid phosphatidylserine (PS) from the internal layer to 
the external layer of the cell membrane. In the presence of calcium ions, 
Annexin V has a high specificity and affinity for PS. Thus, the binding of 
Annexin V to cells with exposed PS provides a very sensitive method for 
detecting cellular apoptosis. The vital fluorescent dye PI is used to 
distinguish between apoptotic and necrotic cells. PI can only enter necrotic 
cells across a damaged plasma membrane. So healthy cells are negative 
for both Annexin V and PI, early apoptotic cells are Annexin V positive but 
PI negative, later apoptotic cells are positive for both, and necrotic cells are 
PI positive completely. 
3.5.1. Primary tumor cell lines UV-B irradiation 
Induction of apoptosis in primary colon cancer cell lines was performed in 
order to obtain a source of tumor antigens, but without the definition of a 
specific tumor antigen, that can be used to set up and in vitro stimulation of 
T CD8+ lymphocytes. During the apoptotic process, bubble shaped balls 
called blebs appear on the surface of the tumor cell. The cell then breaks 
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down into smaller fragments called apoptotic bodies. These fragments are 
enclosed in membranes so as not to harm near-by cells. These apoptotic 
bodies are more likely to be captured by DCs that engulf and process them,  
exposing their peptides in association with MHC I molecules, to T CD8+ 
lymphocytes, without causing an inflammatory reaction. 
Tumor cells (0.2-0.5x106 cell/mL) were placed in 6-well plate and subjected 
to a 200 Grays UV-B irradiation. Before irradiation, medium was removed 
and retained and tumor cells were covered with PBS. After irradiation, the 
original medium (RPMI 1% FBS) was added back to the tumor cells and 
incubated at 37°C, 5% CO2. Early and late apoptosis of tumor cells were 
determined 24-48h after irradiation using Annexin V and PI (Becton 
Dickinson), according to the manufacturer’s protocol. Negative controls 
were performed on not irradiated tumor cells. 
3.5.2. PBMCs and CD4+ T-cells UV-B irradiation  
A weak UV-B irradiation of PBMCs and T CD4+ cells was also necessary to 
achieve the aims of this research project.  
Autologous irradiated PBMCs play the role of feeders for effector cells and 
procure them other sources of APCs.  
T CD4+ cells are subjected to weak UV-B irradiation that causes the 
beginning of the programmed apoptosis path; in this way the T CD4+ 
proliferation is avoided, but keeping on their culture support.  
About 3-4x106 cell/mL of PBMCs and the same amount of T CD4+ cells 
were plated in different 6-well plates and subjected to a 30 Grays UV-B 
irradiation, as the previously described protocol, but in this case, the 
apoptosis of these cells was evaluated by flow cytometry after 24h of 
culture.   
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3.6 Co-culture set up 
After the obtaining of primary tumor cell lines and their UV-B irradiation, 
after the isolation from PB of CRC patients of cell populations of interest, 
and after the UV-B irradiation of PBMCs and T CD4+ cells,  the co-culture 
experiments, based on the stimulation of CD8+ enriched T-cells by antigen-
loaded DCs, could be performed.  
Anti-tumor CTLs were elicited using about 200.000 patient’s DCs as 
antigen presenting cells, about 500.000 irradiated (200 Grays) autologous 
apoptotic tumor cells as the source of tumor antigens, about 400.000 
irradiated (30 Grays) T CD4+ cells, and about 1.000.000 patient’s CD8-
enriched lymphocytes as effectors, in 48-well plate, in IMDM (Lonza) with 
10% of human plasma (Lonza), supplemented with recombinant human 
Interleukin-7 (rh IL-7) (10 ng/ml) (Immuno Tools) and human Interleukin-12 
(rh IL-12) (10 pg/ml) (Miltenyi Biotec). After one week, co-culture will be 
recovered and re-stimulated in the presence of about 1.500.000 adherent 
irradiated (30 Grays) autologous PBMCs, apoptotic tumor cells and low rh 
IL-2 (10 U/ml) (Euroclone) dose, in 24-well plate. The same protocol was 
reiterated for a total of 4 to 5 stimulation cycles, using increasing amount of 
rh IL-2 (up to 100U/mL) (Figure 6). After every stimulation, the percentage 
of T-CD8+ cells was evaluated by flow cytometry. This experimental design 
was similar to the one described by Montagna and colleagues [Montagna et 
al., 2001) 
 
 
 
 
 
 
54 
 
 
                    Day 0                                                                Day 7                                                               Day 14 
 
                                                                                                                    
 
 
          
               1
st 
STIMULATION                                            2
nd
 STIMULATION                        3rd, 4th , 5th, STIMULATION  
Fig.6: Co-culture planning 
3.6.1 Micro-culture set up 
In some cases, the different cell populations obtained were not sufficient to 
set up the co-culture experiment. The primary tumor cell lines, and the T 
CD8+ lymphocytes and the DCs (when the PB samples are inadequate or 
of poor quality) are the more critical cell types for our experiments. When 
one or more of these cell populations were less than expected, a micro-
culture was designed in 96-well plate, keeping the same cell ratio used in 
the co-culture experiment. 
3.7 Monoclonal Antibodies and Flow Cytometry 
Magnetically isolated lymphocytes from PB of CRC patients, and DCs 
obtained after monocytes stimulation with rh IL-4 and rh GM-CSF, were 
assessed by flow cytometry for their specific surface markers. 
Primary tumor cell lines were evaluated by anti-EPCAM antibody. 
After each co/micro-culture stimulation, the CD8+ lymphocytes and their 
viability were used for immune monitoring.  
Briefly, a small number of these cell populations (1x105) were stained in 
FACS Buffer (PBS plus 1% FBS) for 30 minutes at room temperature at 
dark with respective antibodies.  
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Surfce marker analysis of in vitro cultured cells was performed using a 
FACScalibur (Becton Dickinson) and the CellQuest (Becton Dickinson) 
software. We used the following mAbs (all from Becton Dickinson) 
conjugated to: 1) fluorescein isothiocyanate (FITC): anti-CD3, anti-CD14, 
anti-CD83; 2) phycoerythrin (PE): anti-CD8, anti-CD1a, anti-CD80; 3) PE-
Cyanine5 (PeCy5) or Peridinin Chlorophyll Protein Complex (PerCp): anti-
CD11c, anti-CD86, 4) Allophycocyanin (APC): anti-EpCAM, anti-HLA-DR, 
anti-CD4. 
Particularly, lymphocyte populations were analysed using anti-CD45, anti-
CD3, anti-CD8 and anti-CD4 mAbs. 
Monocytes-DCs (day 6 or 7) were phenotyped using anti-CD14, anti-CD1a, 
anti-CD11c, anti-HLA-DR mAbs; DCs maturation was evaluated using anti-
CD80, anti-CD83 and anti-CD86 mAbs. 
7-aminoactinomycin D (7-AAD) (Becton Dickinson) was used to assess 
DCs viability, and that of CD8+ lymphocytes after each stimulation.  
Isotype control antibodies of irrelevant specificities were included as 
negative controls to detect non-specific antibodies binding. 
The percentage of apoptotic primary tumor cell lines, of PBMCs and CD4+ 
lymphocytes subjected to UV-B irradiation was evaluated using specific 1X 
Annexin Binding Buffer, Annexin V FITC-conjugated and PI (Becton 
Dickinson),  according to the manufacturer’s protocol. 
3.8 ELISPOT assay 
The enzyme-linked immunospot (ELISpot) assay was originally developed 
for the detection of individual B cells secreting antigen-specific antibodies. 
This method has since be adapted for the detection of individual cells 
secreting specific cytokines or other antigens. With detection levels as low 
as one cell in 100.000, the ELISpot is one of the most sensitive cellular 
assays available. ELISpot assays employ the quantitative sandwich 
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enzyme-linked immunoabsorbent assay (ELISA): depending on the 
cytokine/factor analysed, it is between 20 and 200 times more sensitive 
than a conventional ELISA. In fact, the ELISpot displays similar sensitivity 
to RT-PCR analysis, but detects secreted protein instead of mRNA, and 
this is a great advantages because often much cytokines are translationally 
regulated.  
Appropriately stimulated cells are pipetted into monoclonal antibody 
(specific for a cytokine) pre-coated 96 wells and the micro-plate is placed 
into a humidified 37°C CO2 incubator for a specified period of time. During 
this incubation period, the immobilized antibody in the immediate vicinity of 
the secreting cells binds secreted cytokine. After washing away cells and 
any unbound substances, a biotinylated polyclonal antibody specific for the 
cytokine is added to the wells. Following a wash to remove any unbound 
biotinylated antibody, alkaline-phosphatase conjugated to streptavidin is 
added. Unbound enzyme is subsequently removed by washing and a 
substrate solution (BCIP/NBT) is added. Blue-black coloured precipitate 
forms at the sites of cytokine localization and appears as spots, with each 
individual spot representing an individual cytokine-secreting cell. The spots 
can be counted with automated ELISpot reader systems or manually, using 
a stereomicroscope. 
3.8.1 Twenty-four hours IFN-γ ELISPOT assay 
The cytokine ELISpot assay has been widely applied to investigate specific 
immune responses in cancer.  
IFN-γ ELISpot assay (ELISpot PLUS for Human IFN-γ, MABTECH) is used to 
monitor CTLs activation against autologous tumor cells, following the 
manufacturer’s instruction. INF-γ ELISPOT analysis were performed,at the 
end of the third, fourth and fifth co-culture stimulation, and, when possible, 
at the end of second and third micro-culture stimulation. 
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Particularly, 96 micro-plates, bought already pre-coated with a monoclonal 
antibody specific for IFN-γ, were washed four times with 200 µL per well of 
PBS (Euroclone) and blocked with 200 µL per well of RPMI 1640 
(Euroclone) containing 10% FBS (Euroclone) for at least 30 min at 37°C. 
After incubation, medium was removed and the cells of co-culture, 
considered as anti-tumor effectors, were added to the plate.  
The anti-tumor effectors were plated in triplicate for 24h alone, with 
autologous irradiated primary tumor cell line, as specific stimulus, o with an 
aspecific stimulus as positive controls.  
Indeed, when measuring antigen-specific T-cell responses in ELISpot 
assay, the presence of positive/negative controls is a crucial step. In our 
assay negative control consists of effector cells in medium without specific 
stimulus, while polyclonal T-cell activator (an antibody specific for CD3 like 
OK3T, GENE TEX) serves as a positive control both for cell viability and 
the functionality of the immunoassay. The plate schemes, with the 
respective cell amounts used in ELISpot assay after a co-colture or a 
micro-culture, are shown in figure 7: 
 
                             
Fig.7: ELISpot Plate representation: each well was performed in triplicate 
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The plates thus prepared were put in a 37°C humidified incubator with 5% 
CO2 and incubated for 24 hours.  
The spots detection was done according to manufacturer’s instructions.  
3.9 Microbiological analysis of primary colon tumor cells 
contaminations 
It is already known that the massive intestinal bacterial flora adversely 
affects the obtaining of colon primary tumor cell line [Antonic et al, 2013]. 
Microbiological analysis were conducted to clarify whether the contaminant 
microorganisms of colon cultures are actually those that reside in this 
anatomic region or not. 
3.9.1 Infectious agents growth on solid medium 
About 100µL of 12 tumor cell lines with clear microbiological 
contaminations were seeded on different solid medium to identificate which 
infectious agent/s caused the contamination of colon cultures.   
Five solid media have been used for this screening: Muller Hinton (MH) 
(Becton Dickinson), Mannitol Salt Agar (MSA) (Becton Dickinson), 
McConkey (MC) (Becton Dickinson), Tryptic Soy Agar (TSA) (OXOID) 
supplemented with serum and Sabouraud medium (OXOID).  
MH is a non selective, non-differential medium. This means that almost all 
microorganisms plated on here will grow. 
MSA is a selective medium, because encourages the growth of a group of 
certain bacteria while inhibiting the growth of others; indeed, it contains a 
high concentration of salt, making it selective for gram positive bacterium 
Staphylococci. It is also a differential medium for mannitol fermentors, since 
it contains mannitol and phenol red as pH indicator.  
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MC is another selective and differential medium, encouraging the growth of 
Gram negative bacteria, and characterizing those able to ferment lactose to 
those that not do that. 
TSA plus serum is a common medium enriched of human serum to 
encourages the growth also of most demanding microorganisms. 
Sabouraud agar medium is a complex medium useful to observe fungi 
growth. 
3.9.2 Gram staining 
Gram staining is a common technique used to differentiate two large 
groups of bacteria based on their differenT-cell wall constituents. The Gram 
stain procedure distinguishes between Gram positive and Gram negative 
groups by coloring these cells pink or violet.  
Gram staining involves three processes: staining with a water-soluble dye 
called crystal violet (Sigma-Aldrich), decolorization, and counterstaining, 
with basic fuchsin (Sigma-Aldrich). Due to differences in the thickness of a 
peptidoglycan layer in the cell membrane between Gram positive and Gram 
negative bacteria, Gram positive bacteria (with a thicker peptidoglycan 
layer) retain crystal violet stain during the decolorization process, while 
Gram negative bacteria lose the crystal violet stain and are instead stained 
by the basic fuchsin in the final staining process.  
Particularly, a colon cell line sample was put on a slide to be stained: the 
slide was carefully passed on a Bunsen burner three times to heat fix the 
sample; the crystal violet was added to the sample/slide for 1’; after a water 
washing, a Lugol solution (Sigma-Aldrich), that is a mordent able to fix the 
crystal violet to the bacterial wall, was addes for 1’; sample/slice was rinsed 
with acetone for 3’’ (if the alcohol remains on the sample for too long, it may 
also decolorize Gram positive cells) and after that, with a gentle stream of 
water; the basic fuchsin was added to the slide and incubated for 1’; a wash 
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with a a gentle stream of water for a maximum of 5 seconds completed the 
protocol staining. If the bacteria is Gram positive, it will retain the primary 
stain and not take the secondary stain, causing it to look violet/purple under 
a microscope. If the bacteria is Gram negative, it will lose the primary stain 
and take the secondary stain, causing it to appear pink when viewed under 
a microscope. 
3.9.3 Catalase and oxidase tests 
In order to differentiate an infectious agent from others, the specific 
enzymatic profile of microorganisms could be used.  
Catalase is an enzyme possessed by some microbial groups. This enzyme  
breaks hydrogen peroxide (H2O2) into H2O and O2. Catalase test (Sigma-
Aldrich) is useful to differentiate Staphylococcus  from Streptococcus 
species; it is performed on a slide where a colony is diluted in a drop of 
H2O2. Catalase producing bacteria (catalase positive) that are usually 
aerobic or facultative anaerobes, release oxygen which forms bubbles. 
Cytochrome c oxidase is a component of the cytochrome oxidase system in 
electron transport chain. This enzyme is present in particular microbial 
groups, and it is able to oxidize aromatic amines-with production of colored 
compounds. Oxidase test (Sigma-Aldrich) is usually used to discriminate 
Micrococcus from Staphilococcus species, in particular to identificate 
Neisseria and Pseudomonas species. The test is performed by dropping a 
well-isolated colony on solid medium, or on loopful of bacteria placed on 
the filter paper containing reactive amine-aromatic: the appearance of a 
purple color indicates a positive reaction. 
All bacteria positive for catalase and negative for oxidase tests were 
subjected to an enterotube test (Becton Dickinson) for Enterobacteriaceae 
members identification.  
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3.9.4 Enterotube test 
Enterotube is a multiple-test system which combines multiple biochemical 
tests useful in identification of members of the family Enterobacteriaceae.  
Titsworth and colleagues described the enterotube procedure and the 
results interpretation in 1969 [Titsworth et al., 1969] and this procedure is 
still in use. 
Enterotube is a self-contained, compartmented plastic tube containing 12 
different media that allow the determination of 15 biochemical reactions 
(glucose, gas production from glucose, lysine decarboxylase, ornithine 
decarboxylase, hydrogen sulfide (H2S), indole, adonitol, lactose, arabinose, 
sorbitol, Voges-Proskauer (VP), dulcitol, phenylalanine deaminase (PA), 
urea and citrate). The enclosed inoculating wire allows inoculation of all 
compartments in one step from one or a few single colonies of an isolate. 
The resulting combination of reactions, together with the Interpretation 
Guide (codebook), allow identification of clinically significant 
Enterobacteriaceae. We used Enterotube tests of Becton Dickinson. 
3.9.5 Minimal inhibitory concentration  
The minimal inhibitory concentration is defined as the lowest concentration 
of antibiotic or antimicotic that inhibits bacterial or fungi growth respectively. 
MIC data consists of growth or inhibition of growth at each concentration 
tested after 24 or 48 hours of incubation at 37°C, starting from an inoculum 
size of 105 colony-forming units (CFU)/ml (grown over night in RPMI 20% 
FBS).  
Usually a stepwise two-fold increase of the antibiotic or antimycotic 
concentrations is used. The antibiotic and antimycotic with respective range 
of concentration tested were shown in Table 2: 
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Drugs Highest concentration Lowest concentration 
Penicillin/streptomycin* 4X 0,12X 
Ampicillin* 400 µg/mL 12,5 µg/mL 
Kanamycin* 400 µg/mL 12,5 µg/mL 
Chloramphenicol* 20 µg/mL 0,6 µg/mL 
Tetraciclin* 20 µg/mL 0,6 µg/mL 
Gentamicin* 800 µg/mL 25 µg/mL 
Amphotericin B* 1 µg/mL 0,03 µg/mL 
Fluconazol** 2 µg/mL 0,07 µg/mL 
Voriconazole** 32 ng/mL 0,7 ng/mL 
Table 2: Concentration range of antibiotics and antimycotics tested in MIC analysis 
* (Euroclone) **(Sigma-Aldrich) 
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4. RESULTS 
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Results regarding the establishment of primary colon tumor cell lines, the 
setting up of co/micro-cultures with respective immunological analysis, both 
cytofluorimetric and enzymatic, are described in the section Results I. 
Results regarding the study of bacterial or fungi colon cell contaminations 
are described in section Results II. 
4.1 Results I 
4.1.1 Case Study 
Starting in 2010, a total number of seventy-eight colorectal cancer patients 
were enrolled in the study. Colorectal tumor tissues were collected during 
surgery in collaboration with San Giuseppe Hospital and Città Studi Clinical 
Institute, Milan. Tumor biopsies, collected from each patient, were analysed 
by pathologists to determine TNM stage and transferred to the laboratory 
as soon as possible, together with a speciemen of PB.  
PB samples were obtained from 65/78 (83,3%) patients and 30/65 (46,1%) 
were not in sufficient amount for performing the experiments.  
The study population’s features were summarized in Materials and 
Methods section. 
4.1.2 Rationale of the study 
ACT immunotherapy involves the reinfusion of immune cells with antitumor 
activity, obtained ex vivo, into cancer patients [Rosenberg et al, 2011; 
Pedrazzoli et al, 2011]. This experimental approach was successful applied 
in several kinds of hematopoietic malignancies and solid tumors.  
Since the results of new therapeutic strategies in CRC were poor and often 
conflicting, we tried to develop an adoptive immunotherapeutic approach 
for CRC patients, retrieving the tumor-reactive T-cells from the PBMCs. 
The rationale of this study is shown in Figure 8 and is based on: 
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 Obtainment of primary colon tumor cell lines, used as source of 
tumor antigens after UV-B irradiation;  
 Generation of DCs, able to capture and to present tumor antigens to 
autologus T lymphocytes, starting from monocytes; 
 Activation of T CD8 lymphocytes (CTLs), that could direct their 
cytotoxic ability against tumor cells secreting IFN-γ.  
 
 
Fig.8: Rationale of our research project 
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4.1.3 Establishment of primary colon tumor cell lines 
Seventy-eight colorectal tumor tissues were collected from 78 CRC patients 
and were subjected to mechanic dissociation by means of GentleMacs to 
obtain a single cell suspension. After several steps of filtering and washing, 
in order to remove all fat residues, cells were cultured in CellGro medium, 
with the defined antibiotic cocktail as described in Material and Methods 
section, to allow their adhesion, expansion and to avoid bacterial or fungi 
contaminations. Nevertheless, 43/78 (55,1%) CRC patients were excluded 
from the study due to bacterial or fungi contaminations of cell cultures. In 
addition 15/78 (19,2%) CRC patients were excluded because the tumor 
cells did not reach a sufficient expansion. Accordingly, the success rate for 
the generation of primary colon cell lines from fresh tumor tissues was of 
25,6%, as primary tumor cell lines were obtained from colon biopsies 
surgically removed from 20/78 CRC patients. Six of the 20 primary colon 
tumor cell lines are shown in Figure 9. 
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Fig.9: Establishment of primary colon tumor cell lines: cell lines obtained from 6 CRC 
patients were shown from A to F panels 
 
The phenotypical features of tumor cells were evaluated by flow cytometry 
using an anti-EPCAM antibody (data not shown). 
 
A B 
C D 
E F 
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4.1.3.1 Morphological and phenotypical changes of primary colon 
tumor cell lines after UV-B irradiation  
UV-B irradiation is considered one of the most powerful approach to 
generate apoptotic bodies from primary tumor cell lines. The apoptotic 
bodies from primary colon tumor cell lines were generated after a 200 
Grays of UV-B irradiation and 48h of culture and were used as source of 
antigens for T-cells activation by DCs. Morphological changes of cultures, 
shown in Figure 10, were assessed by light microscopy. 
 
    
 
 
 
    
 
Fig.10: Morphological changes of primary colon tumor cell lines: A) A primary colon tumor 
cell line before UV-B irradiation; B) A primary colon tumor cell line after 200 Grays UV-B 
irradiation and 48h of culture 
 
 
 
A 
B 
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A cytofluorimetric analysis was performed to determine the rate of apoptotic  
cells obtained after 200 Grays of UV-B irradiation and two days of culture, 
using Annexin V-FITC and PI staining.  
Primary tumor cell lines not subjected to irradiation were used as negative 
control. Non-irradiated primary colon tumor cell lines contained 2-4% of 
physiological late apoptotic cells characterized by annexin V+/PI+ staining, 
while after irradiation at 200 Grays and 48h of culture, about 35-40% and 
20-25% of early (annexin V+/PI-) and late apoptotic cells respectively, were 
obtained (Figure 11). These percentages were enought to induce the 
immune stimulation.  
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Fig.11:Features of apoptotic tumor cells measured by flow cytometry: 
 UV-B irradiation induced early and late apoptosis in primary colon tumor cell lines. In panel 
A, the forward/side scatter (FSC, SSC) dot plot, and the dot plot of Annexin and PI staining 
of a not irradiated tumor cell line were shown. A gate on FSC and SSC dot plot was 
designed to exclude cell debris. In panel B, dot plots of 200 Gray irradiated tumor cells line 
after 48 h of culture were shown. A gate on FSC and SSC dot plot was designed to exclude 
cell debris, and to include cells that, after UV-B irradiation showed an increasing granulosity. 
Early apoptotic cells were defined by the Annexin V
+
/PI
-
 populations, whereas late apoptotic 
cells were defined by Annexin V
+
/PI
+
 populations, and measured by a 2-color flow cytometry 
analysis. Percentage of annexin V
+
/PI
-
 and annexin V
+
/PI
+
 cell populations of control and 
irradiated cell line were shown in the lower right and upper right quadrant of the dot plots 
respectively. 
 
4.1.4 Morphological and phenotypical features of Dendritic Cells 
DCs are the most powerful antigen presenting cells, able to capture, 
process and present the antigens; therefore DCs play a fundamental role in 
activating the maincells involved in the anti-tumor immune response: the T 
CD8+ lymphocytes. 
The approach used to obtain DCs starting from magnetically isolated 
monocytes has been abundantly described in literature. 
2-4% 
20-25% 
35-40% 
A 
B 
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The advantage in employment of magnetic CD14+ beads lies in obtaining a 
higher percentage of pure monocytes (>92%) than that usually given by a 
cell preparation of  CD14+ cells (data not shown). 
These monocytes were stimulated to differentiate in DCs within 6-7 days of 
culture in medium containing rh GM-CSF and rh IL-4.  
The morphological modifications of monocytes differentiating in iDCs were 
monitored by light microscopy (Figure 12); ultrastructural characteristics of 
DCs, such as cytoplasmic projections, abundant organelles and irregular 
nuclei can be observed in panels B, C and D.  
 
 
Fig.12: Monocytes differentiation to iDCs monitored by light microscopy: monocytes were 
cultured in presence of IL-4 and GM-CSF for 6-7 days 
A) Monocytes captured at the day 0 of culture; B) Monocytes-iDCs captured at the day 3 
of culture; C) and D) iDCs captured at the day 6 of culture 
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DCs stimulated by these two cytokines are considered to be immature, as 
reported by flow cytometric analysis. 
In order to study the immature DCs population, the following surface 
markers were analyzed by flow cytometry: CD14+, that is gradually lost 
during the monocytes-DCs differentiation, and CD11c+, CD1a+ and HLA-
DR+, that are specifically expressed on iDCs. Monocytes differentiation 
towards a DCs phenotype caused a marked down-regulation of CD14+ 
positive cells (considering that CD14+ magnetically isolated cells were more 
than 92%) up to about 10% (data not shown). 
The expression of the specific DCs surface markers is shown in Figure 13 
A high expression of CD11c+ and HLA-DR+ surface markers was observed, 
with about 95% of positive cells for both, while about 35% of CD1a+ cells 
were reported.  
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Fig.13: Features of iDCs measured by flow cytometry: dot plot panels showed 
representative data of monocyte differentiation to iDCs. A gate for DCs analysis was defined 
in a dot plot of FSC versus SSC (A); leukocyte population was excluded from the gate. 
CD11c
+
, CD1a
+
 and HLA-DR
+
 surface markers were analyzed. Percentages of cells CD1a
+
 
CD11c
+
,  CD1a
+
 HLA-DR
+
 and HLA-DR
+
 CD11c
+ 
were shown in panels B, C and D 
respectively. 
  
 
 
 
 
 
 
 
 
35% 
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90% 
35% 
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In addition, iDCs viability has been evaluated using 7-AAD. All DCs surface 
markers analyzed were negative for 7-AAD, as shown in Figure 14. 
 
 
Fig.14: DCs viability measured by flow cytometry. The gate R1 used previously for DCs 
analysis was kept. The gate R2, R3 and R4 were designed on CD1a
+
, CD11c
+
 and HLA-
DR
+
 positive cells and shown in the middle dot plot of panel A, B and C respectively. These 
gates, subsequently applied to the three SSC versus 7-AAD dot plots, were shown. 
 
It is already known, even if still under debate, that the so generated iDCs, 
may engulf apoptotic cells and their antigens can be cross-presented for 
the generation of HLA class I/peptide complexes, allowing the induction of 
specific CTLs. 
R2 and R1 
R3 and R1 
R4 and R1 
A 
B 
C 
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4.1.5 Autologous T CD8+ lymphocytes stimulation with dendritic cells 
pulsed with apoptotic primary colon tumor cell lines in co-culture or 
micro-culture experiments 
On the basis of biological samples collected from CRC patients and of their 
amount, three co-cultures and three micro-cultures were set up in order to 
develop a procedure for inducing autologous anti-tumor CTLs.  
It was not possible setting up other cultures because 14/20 (70%) of the 
primary tumor cell lines generated did not have the corresponding DCs.  
The cell components of these cultures, the cytokines used as stimuli, and 
the overall experimental flow chart were illustrated in material and methods 
section.  
A weak UV-B irradiation of T CD4+ lymphocytes and of autologous PBMCs 
has been performed to retain the ability of these cells to supporting T CD8+ 
lymphocytes, but without impairing CTLs expansion. An increasing dose of 
IL-2 was used to allow CTLs expansion. 
Furthermore, the culture conditions promoted DCs maturation, that was 
evaluated by flow cytometry, analyzing some surface costimulatory 
molecules such as CD80 and CD86, and the surface marker CD83 typical 
of mature DCs (data not shown). 
Five weakly stimulations have been performed for each of the three co-
cultures, while three have been done for all the micro-cultures.  
These cultures were very difficult to maintain because of their low 
propensity to expand.  
Morphological features of a cell co-culture were monitored by light 
microscopy at the end of every of the five simulations (Figure 15). DCs, 
after being co-cultured with immunological effector cells, formed typical non 
adherent clusters.  
76 
 
 
Fig.15: Co-culture monitoring by light microscopy: the morphological features of a CRC 
patient co-culture were reported at the end of each stimulation (from the 1
st
 to the 5
th
) from 
panel A to E 
 
In order to identify the subsets of T-cells reacting to the stimulation with 
autologous tumor-loaded DCs, followed by restimulation with irradiated 
tumor cells alone (when necessary), the phenotype of the T-cells from the 6 
CRC patients were analized by flow cytometry at the end of every weekly 
stimulation (data not shown). 
The percentage of T CD8+ cells obtained in the co/micro-culture 
experiments ranged between 7% and 50%. When the percentage of T-cell 
effectors were >10%, T-cell effectors were cryopreserved for subsequent 
analysis at the end of each specific stimulation. Particularly, starting from 
the third stimulation for all the co-cultures and from the second for all the 
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micro-cultures, about 150,000 and 100,000 effectors cells respectively, 
were cryopreserved in order to perform an ELISpot analysis. 
 
4.1.6 Evaluation of the anti-tumor immune response with a 24 hours 
IFN-γ ELISpot assay  
The cytotoxic activity of CTLs was defined by a 24 hours IFN-γ ELISpot 
assay at the end of any specific stimulation, usually from the third to the 
fifth ones for the co-cultures and from the second to the third ones for the 
micro-cultures. 
The 6 co/micro-cultures were evaluated in response to no stimulus, to 
aspecific stimulus such as the monoclonal antibody against CD3 (OK3T), or 
to a specific stimulus with autologous tumor cells, as described in material 
and methods section.  
The example of an ELISpot reader screen, obtained after an ELISpot assay 
on one CRC patient, was reported in Figure 16; the patient effector cells 
were analized for IFN-γ secretion at the end of the third co-culture 
stimulation, as described in material and methods section. 
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Fig.16: Elispot reader results of a representative IFN-γ ELISpot assay: back-ground IFN-γ 
secretion of negative controls, represented by the immunological effectors cultured alone, 
was shown in panel A; the spot forming cells after the immunological effectors culture in 
presence of an aspecific stimuli, such as the monoclonal antibody OK3T, were reported in 
panel B; the IFN-γ production of immunological effectors in response to the autologus tumor 
cells can be appreciated in panel C. 
 
The number of spot forming cells is higher in the wells with autologus tumor 
cells than in the wells with controls. 
An empirical evaluation has been done to determine whether the IFN-γ 
secretion was significant and at which stimulation, using the following 
formula: 
 
 
This formula is based on the number of spots observed in the different 
wells. An histogram representation of all ELISpot results obtained for each 
patients was shown in Figure 17. 
 
 
 
 
[(T-cells + Autologous tumor)  - (Unstimolated T-cells) / (Unstimolsted T-cells )]  > 2 
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Fig.17: Histogram representation of the ELISpot results: 
Six T-cell cultures (from A to F) were evaluated in a 24-hours INF-γ ELISpot assay in 
response to no stimulus or autologous tumor.  
The asterisk indicates a significant secretion of IFN- γ:  
* [(T-cells + Autologous tumor)  - (Unstimolated T-cells) / (Unstimolsted T-cells )]  > 2 
 
 
Results of these immunological analysis showed a strong IFN-γ secretion 
at the end of the third, fourth and fifth co-culture stimulations for one 
patient, and at the second micro-culture for another patient (Figure 17 A 
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and B), whereas a weak secretion was detected at third stimulations (one 
co-culture and two micro-cultures) of three patients (Figure 17 C, D, E).  
T-cells from one patient did not react to the stimulation (Figure 17 F).  
4.1.7 Results summary 
A schematic representation of the obtained results was reported in Figure 
18.  
 
  
 
 
Fig.18: Summary of the obtained results  
 
In this study 78 CRC patients were enrolled. Colon biopsies were collected 
from each of them, while PB was taken from 65 patients.  
Infectious agent contaminations and lack of cell expansion from a side, and 
poor quality and poor amount of PB samples on the other side, have 
compromised a larger immunological evaluations. In fact it was possible to 
setting up only six T-cells co/micro-cultures. 
 
ELISPOT 
ASSAYS 
 
Strong IFN- γ secretion was 
detected at the end of the third, 
fourth and fifth stimulations for 
one patient and at the second for 
another patient, whereas weakly 
secretion was detected at the 
third stimulation of three patients. 
One patient did not react to the 
stimulation 
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However, a T-cell effectors activation, evaluated by means of ELISpot 
analysis for the IFN-γ secretion, has been observed. In particular, strong 
IFN-γ secretion was detected at the end of the third, fourth and fifth 
stimulations for one patient and at the second for another patient, whereas 
weakly secretion was detected at the third stimulation for three patients.  
4.2 Results II 
4.2.1 Infectious agents identification in colon cancer speciemens 
Microbiological analysis were performed on 12/43 (28%) colon cell lines, 
that showed contaminations. In order to verify the presence of infectious 
agents, 100µL of cell culture were seeded on MH, MSA and MC solid 
media; in addition 100 µL were seeded on TSA medium enriched of serum 
to allow the growth of more esigent bacteria in terms of nutrition.  
On the same speciemens, a Gram staining was performed. When 
suspected yeast contaminations were identified by plating staining, the 
microorganism on Sabouraud agar medium.  
In order to proceed on infectious agents identification, catalase and oxidase 
tests were conducted. 
Taken together, the results of these microbiological analysis allowed us to 
identify that the colon cell lines were often contaminated by more than one 
microorganism. Among the Gram negative bacteria, Morganella Morganii 
was found in 33% of cases, Escherichia Coli  and Pseudomonas in  22%, 
while Serratia and Citrobater in 11%. 
Particularly, Gram negative contaminations were found in 42% of colon 
cultures and 33% of them showed yeast contaminations. Gram positive 
contamination was found in association with Gram negative bacteria and 
this type of contamination represented the 8% of the total, while an 
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association between Gram negative bacteria and yeast was found in 17% 
of cases (Figure 19).  
 
Fig.19: Grafic representation of the colon cell line contaminations 
 
All Gram negative microorganisms, negative at the oxidase test, were 
subjected to the enterotube test, to identify which member of the  
Enterobacteriaceae family caused the contamination. Morganella Morgani, 
Escherichia Coli, Serratia and Citrobacter were the identified Gram 
negative microorganisms. 
Pseudomonas Aeruginosa was the identified Gram negative bacteria, 
positive at the oxidase test. 
The only Gram positive bacterium found in the colon cell line belonged 
probably to group D Streptococcus since: the bacteria grew in chains or 
pairs; catalase test was negative and the bacteria growth was observed on 
MH medium. 
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Yeast contaminations were probably due to Candida Albicans (Figure 20). 
                                    
Fig.20: Example of an yeast contamination captured at light microscopy 
 
The types of microorganisms identified as contaminants of primary colon 
cell lines were summarized in Table 3. 
                                     
Table 3: Infectious agents found in the primary colon cell lines 
 
MIC analysis were conducted in order to test the concentration of several 
types of antibiotics and antimycotics able to inhibit bacterial or fungi growth. 
We performed this investigation after 24 and 48 hours of incubation of the 
inoculum of 105 CFU/mL, using gentamicin, kanamycin, 
penicillin/streptomycin, cloramphenicol, and ampicillin as antibiotics and 
fluconazole, voriconazolee and amphotericin B as antimycotics, using the 
range of concentrations reported in the Material and Methods section. 
Results of these analysis were summarized in table 4 for antibiotics and in 
table 5 for antimycotics. 
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M.O. h 
ANTIOBITICS 
Kanamycin Ampicillin 
Penicillin/ 
Streptomicin 
Gentamicin Chloramphenicol Tetraciclin 
Morganella M. 
24h S S S S S S 
48h S R S * S *** R S **** 
Escherichia Coli 
24h S S *** S S R R 
48h S S *** S ** S R R 
Serratia 
24h S S S S S S 
48h R R S S R S **** 
Citrobacter 
24h S S *** S S R R 
48h S R S S R R 
Pseudomonas 
24h S *** R S * S R R 
48h R R S ** S R R 
Streptococcus 
D 
24h R R S R R R 
48h R R S ** R R R 
* until 2x; ** until 4x; *** 400µg/ mL; **** until 20 µg/ mL 
Table 4: MIC analysis: infectious agents sensibility (S) or resistance (R) to antibiotics: 
evaluations after 24h and 48h of incubation 
 
 
M.O h 
ANTIMYCOTICS 
Fluconazole Voriconazole Amphotericin B 
Yeast* 
24h S S S 
48h S S Δ S ΔΔ 
                      * Suspected Candida Albicans; Δ until 0.032ng/mL; ΔΔ until1 µg/mL 
Table 5: MIC analysis: infectious agent sensibility (S) or resistance (R) to antimycotics: 
evaluations after 24h and 48h of incubation 
 
These results showed that many antibiotics were often unable to inhibit the 
bacteria growth in colon cancer cultures. Gentamicin and kanamycin were 
the more efficient antibiotics identified by the MIC analysis.  
Among antimycotics, only fluconazole was able to inhibit the fungi growth. 
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5. DISCUSSION 
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5.1 Immunotherapeutic strategies in cancer 
Antitumor immunotherapy for CRC has been studied for decades. Although 
some clinical trials of cancer immunotherapy have demonstrated a potential 
benefit for patients with CRC, yet immunotherapy remains only an 
experimental option for this disease. 
Usually, immunotherapy targeting CRC takes one of two approaches: 
cancer vaccines or ACT. 
The development of a cancer vaccine is a complex process that needs the 
identification of a suitable antigen target and the design of an appropriate 
vaccine mechanism to elicit immune responses against cancer cells 
expressing that antigen [Xiang et al.,  2013].  
The production of several types of vaccines against CRC, including tumor 
cell vaccines, peptide vaccines, DCs vaccine, DNA vaccine and viral 
vector-based vaccine, has been more diffucult than vaccine development 
against other cancers. The main reason is that TSA, TAA and CTA are less 
expressed in CRC than in other neoplasies [Boncheva et al., 2013].  
Anyway, at least ten-tumor associated antigens and thirty-five major MHC 
restricted epitopes derived from tumor antigens have been identified as 
potential targets also for T-cell mediated adaptive immune response [Line 
et al., 2002, Chan et al., 2010]. 
Although the concept of a preventive vaccine is appealing, current available 
CRC vaccines are applied to activate the immune system to destroy tumors 
once they are detectable, and, therefore, are indicated as therapeutic. 
As reviewed by Merika and colleagues [Merika et al., 2010], there are 
several evidences that the immune system is capable of mounting an 
immune response in CRC, even if it is not always effective in sustaining it 
or the preventing tumor progression. In fact antigenic stimulation may lead  
to the generation of a small population of memory T-cells [Sallusto et al., 
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2004]; a great number of  infiltrating memory T-cells has been associated to 
decreasing of metastasis [Pages et al., 2005], and intra-tumour lymphocytic 
infiltration has been shown not only to inhibit tumour growth [Baier 1998] 
but also to improve overall CRC patients survival [Diederichsen et al., 2003, 
Naito et al., 1998, Galon et al., 2006]. 
However, similar to other cancers, many immune evasion mechanisms can 
be employed by the tumor to escape the immune system responses, even 
if weak. Among these, the shift from Th1-Th2 immune responses, the loss 
or down regulation of HLA class I processing and presentation, the 
defective DCs functions, the T-cell loss of signalling molecules, presence of 
T regs, TGF-β, VEGF and others have been reported [Evans et al., 2010]. 
Anyway, many strategies employed to restore these antitumor responses 
have been studied, and all converged on the necessity to develop vaccines 
or other immunotherapeutic approaches that trigger CTLs responses, Th1 
helper immune responses and to limit the secretion of inhibitory cytokines 
or the action of inhibitory cell populations. 
The main aim of this research project was the development of an ACT 
approach, potentially useful to introduce a new therapeutic strategy for 
CRC patients in a near future. 
Our study was designed starting from the evidence that ACT was 
successfully applied in melanoma and RCC patients. Additionally, the best 
demonstration of the ACT clinical efficacy was reported for EBV-induced 
lymphoma, using EBV-T specific cell lines and CTLs.  
ACT with TIL is an example of a specific, adoptive approach to the therapy 
that has been proven to be an effective treatment for metastatic melanoma 
patients. ACT involves the isolation and the identification of antitumour T 
lymphocytes, from fresh patients biopsy speciemens, and their ex vivo 
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growth, followed by their infusion into the cancer patient [Rosenberg et al., 
2009].  
Dudley and coworkers reported that among 93 metastatic melanoma 
patients treated with TIL selected for tumor recognition, an evident 
response was observed in 50-70% of them, including 15 patients who had 
complete responses [Dudley et al., 2010].  
A comparison of the several published studies on ACT protocols and  their 
clinical efficacy in melanoma patients, such as the adoptive T-cell transfer 
trials currently recruiting patients, were reviewed by Hershkovitz 
[Hershkovitz et al., 2010]. 
There are many reasons for which melanoma has improved the knowledge 
of cancer immunology, first of all the relative accessibility of melanoma 
lesions and the fact that melanoma is one of the easiest cancers to adapt to 
tissue cultures [Maio, 2012], event that allows the identification of TAA, 
CTA and TSA earlier than in many other tumors with different histotypes 
[Houghton et al., 2001, Boon et al., 1996].  
One of the possibilities for improving ACT for metastatic melanoma and 
other cancer patients is based on the transfer of genetically modified 
peripheral T-cells instead of TIL, mainly inducing T-cells to express TCRs 
or CARs specific for various target tumor antigens. 
The frequent toxicity is one of the side effects of these trials. Skin and eyes 
toxicity has been reported in clinical trials targeting the gp100 and MART1 
antigens, even if a melanoma regression was observed [Johnson et al., 
2009].  
Similar events were reported in RCC, in which carbonic anhydrase IX 
(CAIX), overexpressed in both tumoral and normal liver, small intestine and 
gastric mucosa [Leibovich et al., 2007], has been targeted by T-cells 
expressing a CAIX-specific CAR. An autoimmune cholangitis with no 
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clinical objective tumor regression was observed [Lamers et al., 2006 and 
2013]. 
During a CRC ACT clinical trial, autoimmune colitis events occurred in all 
patients treated  with T-cells expressing a TCR with high affinity for CEA, 
that is overexpressed in CRC, but also present in healthy digestive tract. 
Additionally, Morgan and colleagues [Morgan et al., 2010] reported severe 
side effects in CRC patients after the treatment with Her2-specific CAR T-
cells. 
Taken together, these clinical trial results show that autoimmune toxicity 
arises when critical normal tissue expresses antigens intentionally or 
unintentionally targeted by the injected T-cells; this is one of the reasons  
why the identification of CTA, not expressed in normal adult tissue, could 
be very important for cancer immunotherapy. In addition, a second type of 
toxicity, stemed from high cytokine concentration released by the 
engineering T-cells, could be observed in ACT protocols. However, several 
approaches to control these phenomenons have been used or are in 
development, such as the T-cells engeneered to express inducible suicide 
gene in association with TCR or CAR genes [Di Stasi et al., 2011]. Another 
strategy is the engeneering of T-cells together with TCR and CAR targeting 
different tumor antigens, in order to decrease the possibility that those 
could be simultaneously expressed on normal tissues.  
On the basis of the few literature results on the immunotherapeutic 
approaches in CRC, their safety and efficiency, we have designed the 
groundwork to develop a new immunotherapeutic strategy in CRC patients, 
starting from colon biopsy and from the isolation of immune cells from PB, 
overpassing the isolation of TIL since some studies on this lymphocyte 
population were already done. 
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Montagna and colleagues [Montagna et al., 2004] have investigated a 
procedure to obtain in vitro a large amount of anti-tumor HLA restricted 
CTLs, through the stimulation of patient’s CD8+ enriched T-cells, isolated 
from PB, with DCs pulsed with apoptotic solid tumor as source of tumor 
antigens. In this way the hard steps of tumor antigens identification and 
molecular definition are not required. 
5.2 Dendritic cells as antigen presenting cells 
First of all, to discuss the results obtained in our work it is necessary to 
underline which procedure has been chosen to generate DCs and the 
benefits of using apoptotic tumor cells as source of tumor antigen. 
The main functions of DCs, their features based on their maturation status, 
their concentration in PB, their specific surface markers, their use in cancer 
vaccine strategies and in ACT protocols have been already decribed in the 
introduction section. Due to DCs low concentration in PB (about 0,01%), 
several methods have been developed to enriched the DCs population in 
vitro. At the beginning, DCs were obtained starting from the plastic 
adherence of CD14+ monocytes from PBMC, followed by 5-7 days 
incubation with rh GM-CSF and rh IL-4 containing medium [Sallusto et al., 
1994, Gluckman et al., 1997, Palucka et al., 1998]. Recently, monocytes 
have been selected by CD14+ positivity, using a magnetic activated cell 
sorting with magnetic beads, following PBMCs isolation by density 
centrifugation by Ficol-Paque, in order to obtain a high level of purity of 
monocytes. Many  studies use magnetic labeling to obtain monocytes with 
high purity [Duddy et al., 2001], as well as other cell populations. The 
percentage of monocytes purity generated with this method was comprised 
between 90-98%, as reported from Miltenyi Biotec, and also our results 
were in accordance with this percentage: about 92% of CD14+ cells were 
93 
 
obtained after PBMCs magnetig labeling with CD14+ microbeads (data not 
shown). 
In a study of Elkord and co-workers [Elkord et al., 2005] the impact of these 
two different methods, based on plastic adherence or magnetic labeling of 
monocytes, on DCs functionality has been investigated. The authors 
showed that the procedure used to isolate monocytes may influence the 
DCs ability to express costimulatory molecules, maturation markers and to 
produce immunomodulatory cytokines. In particular, DCs derived from 
adherence-isolated monocytes secreted higher levels of IL-12, IL-10 and 
TNF-α than DCs grown from MACS-isolated monocytes. IL-12 has been 
shown to increase IFN-γ secretion from natural killer (NK) cells and T-cells 
and the cytolytic ability of these cells, promoting the development of 
Th1/Tc1 immune responses [Emtage et al., 2003]. However, IL-10 
secretion blocks DCs maturation by interfering with the up-regulation of 
costimulatory molecules and IL-12 production, thereby limiting the ability of 
DCs to promote Th1/Tc1 responses. The inability of MACS derived DCs to 
secrete significant amounts of cytokines is probably caused by blocking of 
CD14 molecules by anti-CD14 microbeads, but the exact mechanism is still 
unclear [Elkord et al., 2005]. This is the reason why CRC co-cultures need 
human IL-12 containing medium, while the inhibition of immunosuppressive 
cytokines secretion is an advantage of the monocytes magnetic isolation 
methods. 
Our results showed that morphological features of DCs obtained from 
CD14+ magnetic labeling were comparable to those obtained with the same 
protocols by Daddy and colleagues [Duddy et al., 2001], but also to those 
obtained by Heo [Heo et al., 2009].  
Regarding the cytofluorimetric analysis, employed to investigate the 
phenotypic features of DCs, we observed that DCs expressed surface 
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markers of immature DCs and lost CD14+ monocyte surface marker. In 
particular, CD11c and HLA-DR surface markers expression were 
comprised between 90-95%, while CD1a between 35-40%. CD14 positive 
cells were less than 10%. These data were in accordance with others 
reported in literature [Mucci et al., 2009, Duddy et al., 2001, Von Euw et al., 
2007].    
The level of DCs maturation was also evaluated in the co-culture, using an 
antibody against CD83, an immunoglobulin member that has been shown 
to be up-regulated following DCs maturation [Elkord et al., 2005, Zhou et 
al., 1996], and antibodies against the costimulatory molecules CD80 and 
CD86 (data not shown). Indeed, in contrast to studies that performed the 
DCs maturation after antigen-capture but before the antigenic presentation 
to T-cells, our co-culture experiments were setting up to allow DCs 
maturation immediately after the antigen presentation to T-cells. 
5.3 Primary colon apoptotic cell lines as source of tumor antigens 
In this study, apoptotic CRC primary tumor cell lines have been chosen to 
deliver tumor antigens to DCs during ex vivo manipulations. The principle of 
this approach is that DCs could present tumor derived epitopes to CD8+ 
lymphocytes, as others do using different sources of tumor antigen. The 
effector cells, once activated, may  infiltrate the tumor tissue, recognize the 
tumor antigens and kill the tumor cells, a process largely studied in mouse 
models [Boissonnas et al., 2007]. 
Therefore, our approach for preparing and loading tumor antigens on DCs 
was designed using a whole tumor cells for the induction of multiple 
antigen-specific policlonal CTLs, in contrast to those that use a single 
tumor-associated antigen for the induction of a single-specific monoclonal 
CTL.  
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Indeed, unlike specific and known tumor associated peptide antigens, 
whole tumor cells may better apply to many neoplasies for which few or no 
defined TSA are available, like CRC. In addition, targeting a single TAA or 
TSA may induce the immune escape of some cell clones which 
downrugulate the specific antigen. On the other hand, the main 
disadvantages of this method included a substantial need of tumor material 
surgically removed and the difficulties of the immunological monitoring in 
the absence of known target antigens.  
In a study by Yasuda and coworkers, the efficacy on anti-tumor immunity  
of four different strategies for pulsing DCs with whole tumor cell antigens 
was evaluated in a murine model of colon cancer [Yasuda et al., 2006]. 
These strategies included DCs pulsed with tumor lysate, freeze-thawed 
necrotic tumor cells, irradiated apoptotic tumor cells and DC/tumor cell 
hybrids.  Tumor stressed cells, including both apoptotic and necrotic tumor 
cells, could be captured  and processed through MHC class I and II 
presentation pathways. Therefore, DCs pulsed with these sources of tumor 
antigens can prime tumor-specific CTLs and Th cells. Despite the fact that 
the best immunological results of this research group have been achieved 
with DC/tumor cell hybrids, similar to those reported by Galea-Lauri et al 
[Galea-Lauri et al., 2002 and 2004] and Kao et al [Kao et al., 2005], it has 
been shown that irradiated apoptotic tumor cells were able to activate a 
more powerful anti-tumor response than what freeze-thawed necrotic tumor 
cells and tumor lysate did in this model.  
A critical analysis on the reason why the use of apoptotic tumor cells is 
better than necrotic cells to induce an anti-tumor immune response was 
done in a very recent work by Buckwalter [Buckwalter et al., 2013]. The 
authors also reported the different opinions and results obtained in other 
studies on wheter apoptotic or necrotic deaths are immunostimulatory 
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phenomena. They clarified, through in vitro  and in vivo investigations, that 
apoptotic cells are significantly more immunogenic than necrotic cells, even 
if the antigenic repertory was the same for the two cell populations. It has 
been also reported that necrotic cells did not have any immunosuppressive 
or tolerogenic features, and both could be taken up by DCs in an equivalent 
manner. An important difference between the use of apoptotic or necrotic 
tumor cells is that the T CD8+ cells elicited by apoptotic cells expand, 
accumulate, and express effector functions, while those primed by the 
necrotic cells do not [Buckwalter et al., 2013], because necrotic cells fail to 
engage CD40, lacking immunogenicity. These results showed that despite 
apoptotic death is a physiological process, apoptotic cells are perfectly able 
to elicit an immune response, trasfering the antigens for cross-presentation 
to DCs, that are able to present the antigens to T naïve cells. A possible 
explanation for the absence of autoimmune responses during apoptosis 
could be found on the fact that the “physiological apoptotic cells” express 
self components, while non-self components, able to induce a T-cells 
activation, may be often found in apoptotic tumor cells. 
We observed that the optimal percentage of about 35-40% of early 
apoptotic primary CRC cell lines can be obtained after 200 Grays UV-B 
irradiation and 48h of culture; this experiment was optimized using different 
grades of irradiation and time of incubation, such as 24, 48 and 72h, after 
UV-B irradiation (data not shown). The morphological changes of primary 
tumor cell lines after the optimized experimental conditions showed the 
generation of apoptotic bodies, also called blebs, that are more easily 
captable by DCs, able to present the antigens in association with MHC 
class I molecules to CTLs. 
In this project, the ability of DCs to capture the apoptotic bodies was not 
evaluated singularly. In contrast with other studies that pulsed DCs with 
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apoptotic tumor cells or other sources of tumor antigens before starting the 
T-cell stimulation, we performed simultaneously the antigens-DCs uptaking 
and the DCs cross priming to the T-cell effectors, given an overall 
consideration after the co-culture experiments. This procedure was 
necessary in order to reduce the lost of DCs and tumor cells during the 
steps culture  and may represent an experimental limitation, because we 
could not verify the efficiency of the antigen up-taking. At the end of the co-
culture stimulations, an efficient antigen presentation was supposed to 
have occurred, if IFN- γ was detected.  
5.4 Success rates of colorectal cancer cell lines establishment  
The scarse evidence that CRC may induce tumor specific T-cell responses 
in an autologous setting [Dalerba et al., 2003], contrary to other cancer 
such as melanomas, could be due to the difficulty in obtaining stable CRC 
cell lines. 
As reported in results section, althogh 78 CRC patients were enrolled in 
this study, and although colon biopsies were collected during surgery from 
each of them, just 20/78 (25,6%) CRC cell lines were obtained. 
Numerous previously studies have reported the difficulty to initiate cancer 
cell lines from fresh surgically removed colon tumors [Namba et al., 1983, 
McBain et al., 1984, Kirkland et al., 1986, Oh et al., 1999]. However our 
success rate of 25,6% in obtaining primary tumor cell lines from colon 
biopsies was higher than those reported in other studies cited. In 2007, a 
very interesting study was conducted by Dangles-Marie and colleagues 
[Dangles-Marie et al., 2007] in order to increase the success rate of cell line 
establishment by engrafting tumor fragments in immunocompromized mice 
before the in vitro culture step. Additionally, a comparison between the cell 
lines obtained directly from tumor speciemens and from the corresponding 
established xenografts was made. Thirtyone surgical speciemens were 
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used for the direct in vitro establishment protocol: only 3/31(9,7%)  
speciemens grew immediately in cell culture. Since all the cell lines were 
generated from primary tumors and none from colon metastasis, the 
success rate in establishment of CRC lines from fresh primary tumors was 
comparable to that obtained in our project (25,6%), Otherwise, a better 
success rate was obtained by the authors after xenotransplantation: briefly, 
20 xenografts were established from 26 tumor speciemens (77%) and 47% 
of cell lines were generated. Half of them was obtained from primary 
tumors and half of them from tumor metastasis. In addition, they 
demonstrated that colon cancer cell lines obtained from xenografts grew 
faster than those generated directly from primary tumor. Conversly, in 
2011, Sarrabayrouse and coworkers were able to obtain only one (5,8%) 
tumor cell line from 17 primary CRC speciemens [Sarrabayrouse et al., 
2011].  
5.5 Infectious agents’ contaminations in colorectal cancer cell lines 
The massive intestinal bacterial flora adversly affected the obtaining of 
colon primary tumor cell lines from fresh colon biopsy; indeed, the main 
problem was represented by microbiological contaminations of the cultures, 
despite a large antibiotics and antimycotics spectrum was used. 
Penicillin/streptomycin, gentamicin and amphotericin B (fungizone) were 
added in the transport medium of the biopsies, and also in the medium 
culture. Neverthless, the percentage of colon cell lines contaminations 
found in this study was of  43/78 (55,1%). 
In a recent review by Antonic and co-workers [Antonic et al., 2013], the 
current level of evidence that either supports or countradicts that the 
infectious may contribute to the development of CRC, was summarized and 
critically assessed. Physiologically, colon is populated by about 1014 
bacteria; these resident bacteria are fundamental in the development and 
99 
 
function of the mucosal immune system; they help to prevent the 
pathogenic bacteria colonization and are useful to maintain the 
physiological microenvironment. It has been hypothesized that the 
presence and the quantity of bacteria in this anatomic district could favor 
the development of CRC, with a risk factor 12-fold higher compared to the 
small  intestine and other gastrointestinal tracts, that contains less bacteria. 
In a study by Tjalsma and colleagues [Tjalsma et al., 2012] a model called 
“driver-passenger” has been proposed to identify some of the mechanisms 
by which bacteria could affect normal or susceptible cells, inducing a 
malignant phenotype. In addition, using a nex generation genomic 
sequencing approach, they proposed that each stage of CRC development 
could be associated with a specific pathogen(s) [Tjalsma et al., 2012]. The 
identification of bacteria involved in early stages of CRC development could 
be useful to perform both an early tumor diagnosis and to identify subjects 
with a higher risk to develop CRC. 
Recent studies described the role of infectious agents as risk factor in the 
development of CRC, and also as drivers of tumorigenic process. Thus, we 
tried to clarify  the origins of the cell lines’ contaminations, in particular to 
improve the protocol for the establishment of primary tumor cell line, 
starting from fresh colon biopies.  
As reported in the results II session, the infectious agents found in colon 
cultures were mainly commensal microorganisms of intestinal tract, able to 
cause opportunistic infections. Enterotubes allowed us to identify 
Morganella Morganii, Escherichia Coli, Citrobacter, and Serratia, whereas 
by means of other tests, Pseudomonas, groups D Streptococcus and 
yeasts have been identified. 
Results of MIC analysis underlined that many antibiotics, generally used in 
cell biology but also extensively used for the therapy, even if  tested at very 
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high concentrations, were unable to inhibit the growth of infectious agents 
in colon cancer cultures. Gentamicin and kanamicin were the antibiotics at 
the largest spectrum identified by the MIC analysis. Unfortunately, the 
gentamicin, that was always added in our cultures, was not sufficient to 
contrast the infectious microenvironment, probably because of the 
presence of various types of microorganisms. The same observation 
should be done about the antimycotics, since only fluconazolo was able to 
inhibit the fungi growth. However, this is an antimycotic of new generation, 
and neither its use in cell culture nor the tolerable concentration have been 
yet established. These results on colon cell culture contaminations are in 
agreement with the great difficulties previously reported to obtain primary 
tumor cell lines from colon biopsies. 
In a recent work by Wang and co-workers Bacteroidesfragilis, 
Enterococcus, Escherichia/Shigella, Klebsiella, Streptococcus and 
Peptostreptococcus were found significantly more often in the gut 
microbiota of CRC patients than in the healthy volunteers [Wang et al., 
2012]. Among them, Klebsiella (Pneumoniae), Streptococcus (bovis), 
Escherichia Coli, together with Helicobacter Pylori and Fusobacterium 
[Reviewed by Antonic et al., 2013] showed to be more strongly involved in 
CRC development. In our study, on 12 colon culture investigated, 2/12 
(16,6%) were due to Escherichia Coli, and 1/12 (8,3%) to a group D 
Streptococcus, but these data are not sufficient to speculate on a possible 
role of these agents in CRC development. In addition, the experimental 
conditions of our microbiological analysis do not permit us to exclude 
Helicobacter Pylori as contaminant agent of the colon cultures. Indeed, the 
difficulty of growth of H.Pylori is very well known, as well as its association 
with the CRC development, that was largely described in a review by 
Antonic and co-workers [Antonic et al., 2013]. Finally, the strong presence 
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of yeasts in our culture, particularly of suspected Candida Albicans (6/12, 
50%), led us to consider that the chemotherapic regiments of CRC patients 
could have increased the adhesiveness of yeasts to the gut mucosa.  
5.6 Ex vivo T-cells stimulation against autologous tumor 
Despite the great difficulties met in obtaining the primary colon cell lines, 
we have set up 3 co-cultures and 3 micro-cultures in order to activate, in 
autologous manner, the CTLs against the autologous tumor.  
A cytofluorimetric analysis to evaluate the percentage of CTLs obtained at 
the end of each stimulation of both co-cultures and micro-cultures was 
done (data not shown). Since T-cells behavior was fluctuating in the 
co/micro-cultures, we established that T-cell effectors should be subjected 
to subsequent analysis when their percentage was higher than 10%. 
However, an increased amount of CTLs was observed up to the end of the 
third stimulation, while a progressive decreasing was observed after that 
(with the exception of on patient in which the percentage of CTLs is 
increased during all stimulations). We hypothesized that this decreasement 
could be due to a reduction of cell viability, despite the progressive stimulus 
with increasing doses of rh IL-2, and to a not effective T CD4+ irradiation. 
Indeed, in some cases, it was possible that Th, that did not successfully 
completed the apoptotic death process, subtracted cytokines and the 
nutrients to CTLs, preventing their expansion.  
A similar approach was developed by Kurokawa and colleagues in RCC 
[Kurokawa et al., 2001], one of the most immunogenic known tumor. Both 
tumor lysate and apoptotic bodies were used as source of antigens for 
loading DC at 3:1 (tumor:DC) ratio and were kept in culture for 24h; 
subsequently DCs maturation was performed adding the lipopolisaccaride 
(LPS) to the culture. Then tumor-specific CTLs were generated co-culturing 
PBMCs with autologous irradiated tumor cells, and weekly stimulation was 
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performed , either with antigen-loaded DCs or irradiated tumor cells. The 
authors showed a temporary descrease of T CD8+ lymphocytes (from 
35,3% at the beginning of co-culture, to 5,3% at day 14)  and an increase of 
T CD4+ cells (from 40% to 85%) after 2 weeks of stimulation. Later on they 
showed a decrease of T CD4 cells (up to 18,6%) and an increase of T 
CD8+ lymphocytes (up to 79,6%), after 4 weeks and additional 
restimulations with irradiated autologous tumor cells alone. The authors 
have analyzed those results underlining that: 1) the use of tumor cells alone 
as stimulator cells generated a NK cell population; 2) the use of tumor-
loaded DCs alone led to induction of CD4+ T helper response after 4 weeks 
of culture; 3) only the sequential induction protocol of a 2-week starting 
culture with tumor-loaded DC followed by tumor cells alone was efficient to 
generate high numbers of tumor specific CTLs [Kurokawa et al., 2001].  
On the basis of these results, in our immunotherapeutic study on CRC, 
effector cells were stimulated with DCs able to load apoptotic tumor cells, 
and weekly restimulated with tumor cells alone. The presence in co-culture 
or micro-culture of weakly irradiated T CD4+ lymphocytes should guarantee 
the immunological support to T CD8+ lymphocytes, without interfering with 
their specific anti-tumor activation.  
An important demonstration of clinical utility of anti-tumor CTLs in adoptive 
immunotherapeutic strategies, also in solid tumor, was achieved by Turin 
and co-workes [Turin et al., 2007]. In this study 4 patients affected with 
solid tumor (1 RCC, 1 ovarian cancer and 2 sarcoma) were enrolled; a 
large amount of autologous anti-tumor CTLs were produced for each of 
them, in compliance with Good Manufacturing Practices (GMP), for in vivo 
use.  
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5.7 Immunoenzimatic evaluation of T-cells activation 
The main goal of monitoring antigen-specific T-cell responses in 
immunotherapy trials is to determine whether treated patients mounted a 
response following an immune intervention, and whether the detected 
response is associated with clinical event. In our ex vivo study, the 
definition of the immune response is a prerequisite for hypothesizing their in 
vivo clinical relevance. 
IFN-γ is one the main cytokines able to induce opposing effect on tumors, 
and its role in promoting antitumor immunity has been exensively reviewed 
by Brassard et al., 2002, Dunn et al., 2006 and Ikeda et al., 2002 and 
colleagues.  
Several IFN-γ detection methods have been developed and are 
commercially available, all with specific discriminating features. These 
methods include mainly ELISpot assay, ELISA, and Intracellular Staining 
(ICS). In the ELISA assay, the cytokine of interest is searched and 
quantified in the cell culture supernatant using antibodies for the specific 
capture and detection, and measuring the release of the product of a 
substrate’s color reaction [Cox et al., 2006]. This assay, in contrast to 
ELISpot, gives no information about individual cells and cannot be used to 
enumerate the reactive cells [Clay et al., 2001]. Indeed, the main difference 
between ELISA and ELISpot is that the first one measures the total amount 
of a cytokine released from all cells in the test, while the ELISpot assay 
detects the release of the cytokine from a single cell. Various studies 
supported the higher level of sensitivity of the ELISpot compared to the 
ELISA assay [Ekerfelt et al., 2002, Mäkitalo et al., 2002, Cox et al., 2006]. 
Nowadays, the ELISpot assay is used in a wide range of application, 
including the monitoring of immune responses of cancer patients 
undergoing immunotherapeutic treatment, the monitoring of the vaccine 
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responses, and during infectious, neoplastic and autoimmune diseases 
[Cox et al., 2006]. However, one of the disadvantages of the ELISpot assay 
is the inability to define the exact phenotype of the cytokine-secreting cells. 
Consequntly, the ELISpot assay experimental design, that includes 
opportune controls is foundamental to be sure that the cytokines production 
is attributed to that specific cellular type. This inconvenience is not present 
in the ICS method, that followed by cytofluorimetric analysis, so that, both 
the intracellular trapped cytokines and the surface markers can be detected 
and the exact phenotype of the cell secreting the cytokine could be 
determined [Maecker et al., 2005]. Several studies have been designed to 
investigate the reproducibility of the results obtained using these three 
cytokines detection methods [Asemissen et al., 2001, Karlsson et al., 2003, 
Letsch et al., 2003, Sun et al., 2003, Tassignon et al., 2005, Whiteside et 
al., 2003]. They are substantially comparable and the choise of the method 
depends by the experimental design and aims. We have chosen the 
ELISpot assay to evaluate the CTLs IFN-γ secretion at the end of each 
co/micro-culture stimulation, because of high sensibility and reduced 
required material, compared to both ELISA and ICS. The choise of positive 
and negative controls was very important for the validation of results. As 
negative controls the effector cells were cultured alone, in order to detect 
the secretion of IFN-γ in response to no stimulus. Positive controls, were 
represented by the effector cells cultured in presence of an antibody 
against CD3, called OK3T, that is a polyclonal T-cell activator. The specific 
stimulus for T-cell effectors was represented by a specific ratio of 
autologous primary tumor cells. 
The results of the ELISpot were analysed using empirical evaluations, 
frequently reported in literature [Lewis et al., 2000, Janetzki et al., 2005, 
Cox et al., 2005, Dubey et al., 2007], even if many other statistical methods 
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have been proposed for the immune response determination [Hudgens et 
al., 2004, Moodie et al., 2006]. Both statistical and empirical methods have 
strenghts and limits and they are alternatively used depending on the need 
of the design. The Student’s t test [Herr et al., 1998] is the most commonly 
used, due to the easy calculation of the p value. It assumes that the 
samples size is large enough to assume that the test statistic follows a 
Student’s t distribution or that the data are normally distributed [Moodie et 
al., 2010]. However, ELISpot data do not always satisfy these assumptions. 
Indeed, this test could not be used in our study, because triplicate wells 
were analyzed for each experimental condition and the responses were 
count data not normally distributed. Alternatively, two not parametric 
statistic tests described by Moodie and colleagues [Moodie et al., 2006], 
called distribution free resamplig (DFR(eq) and DFR(2x)) could also be 
used for our study, but our choise fell on the empirical evaluation. 
One of the empirical rules described by Moodie and co-workers [Moodie et 
al., 2010] was used for the interpretation of the ELISpot results: a response 
was considered positive when a difference of more than twofold between 
the spot counts in the experiment versus those in the background wells was 
observed. Applying this rule, no minimum spot number is required. The 
second empirical rule decribed by the authors defines a positive response 
on the basis of a threshold of 5 spots per 100,000 PBMCs, in the 
experiment wells and an increase of two fold in the spot number over back-
ground. This second rule could also be applied in our evaluation, since we 
always observed more than 5 spots in the experiment wells and, in 
addition, the quantity of effectors plated was less than that reported 
(10,000/well). The advantage of this second rule is the lower percentage of 
false positive rate compared to the first empirical rule (3% and 17% 
respectively). A second important factor to consider is the limit of detection 
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of the ELISpot assay. Generally, the limit of detection is defined as the 
lowest amount of analyte which can be detected in a sample but not 
necessary quantified as an exact value. For the ELISpot analysis a signal-
to-noise approach, that compares the spot count in the experiment wells 
(signal) with the spot counts in the medium control wells (noise) could be 
applied. The ratio between signal and noise must be comprised between 
2:1 to 3:1.  However, to increase the power of both empirical and statistical 
tests, it would be ideal to have more replicate wells for both control and 
experimental condition. It has been demonstrated that even an increased 
number of the replicates for the controls would already increase the power 
to detect an immune response [Hudgens et al., 2004, Moodie et al., 2006]. 
Anyway, at present, the number of effectors obtained after co/micro-culture 
not allows to add further control wells. 
Taken together these results showed that, although our immunological 
study must be done on an increased number of CRC patients, and the 
CTLs lytic ability against autologous tumor cells must be performed, it can 
be hypothesized that the generation of tumor-specific CTLs activated ex-
vivo against tumor could be useful for supporting ACT in CRC. 
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6. CONCLUSION 
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ACT has been developed as a therapeutic approach for tumors arising from 
the hematopoietic system, such as acute and chronic myeloid leukemia, 
lymphoma and multiple myeloma [Montagna et al., 2001].  
Subsequent literature studies published the use of a similar strategy also 
for solid tumors, such as melanoma and RCC, two types of neoplasia that 
appear exceptional in their ability to stimulate spontaneously the anticancer 
endogenous immune cells [Kurokava et al., 2001]. 
The process of tumor progression involves complex interactions among 
different cells of the immune system and different effector molecules. The 
effector T lymphocytes are the key players that prevent the tumor 
development and inhibit the tumor progression [Dunn et al, 2004]. The 
PBMCs isolated from the blood of RCC patients were stimulated in vitro 
with tumor-loaded DCs. A primary T-cell response against RCC was 
elicited and expansion of tumor-specific CTLs for adoptive transfer was 
achieved. It was demonstrated that restimulation with autologous irradiated 
tumor cells alone was optimal for the induction of tumor specific CTLs in 
vitro. These CD8+ T-cells exhibited strong MHC class I-restricted cytotoxic 
activity against the autologous tumor [Kurokava et al, 2001]. 
In our study a new immunotherapeutic approach for CRC was developed. 
The interest of the scientific community for this tumor is very high, because 
it is one of the most common diagnosed cancers wordwide. In addition, 
although CRC mortality has decreased during the last years, it remains the 
third cause of cancer related mortality. Improving methods of diagnosis and 
therapeutic possibility for CRC patients are objectives to be achieved. 
The adoptive immunotherapeutic approach proposed in our study was 
focused on: 1) the establishment of primary colon cell lines from colon 
biopsies; 2) the obtainment of DCs from monocytes and of T lymphocytes 
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by means of PBMCs magnetic labeling; 3) the activation of autologous anti-
tumor CTLs in co/micro-culture experiments.  
The evaluation of the T-cells activation was performed using an ELISpot 
assay specific for the IFN-γ production. The biological functions of this 
cytokine include both direct cytotoxic antiproliferative effects on tumor cells 
and stimulation of adaptive immune system cells against tumor antigens. 
Our protocol suffered of some limitations that should be avoided: first of all, 
often the biological speciemens were not enough to perform the 
immunological confirmatory evaluations to set up further controls. For 
example, the IFN-γ secretion after co/micro-culture stimulation would have 
been evaluated by ICS. In fact, by evaluating also the cell surface markers, 
IFN-γ secretion could be confered to CTLs with absolute certainty. 
Similarly, even if the absence of NK cells in co/microculture was confirmed 
by flow cytometry, additional ELISpot controls should established with 
effector cells cultured with the leukemic cell line K562, in order to exclude 
the IFN-γ production by contaminant NK cells. Additionally, another 
ELISpot control should be composed by the effector cells cultured in 
presence of DCs not loaded with tumor antigens. 
Although our results suggested that CTLs activated ex vivo against the 
tumor could be useful for supporting the ACT protocols, two main aims 
need be achieved in the near future, to complete this study and to validate 
its scientific relevance as new therapeutic strategy of CRC.  
The first aim is the CTLs expansion: the effector cells that secreted IFN-γ 
were criopreserved for this purpose. We are planning to perform the CTLs 
expansion following previous published protocols. Briefly, after tumor-
specific stimulations, CTLs will be further expanded in presence of 
autologous irradiated feeder cells, OKT3 and of a low dose of rh IL-2. The 
rapidly expanded cultures will be maintained for about 15 days. After the 
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first round of antigen-independent expansion, specificity and sterility tests 
will be performed to confirm the quality of the product, and then a second 
cycle of expansion will be conducted. At the end of the process and before 
cryopreservation, CTL lines will be tested again for their cytotoxic activity 
against autologous tumor and for microbial contaminations.  
The second aim is the assessment of the cytotoxic activity of the CTL lines 
against autologous tumor (CTLs should be able to lyse patient tumor cells). 
We are planning to use for this analysis a  51Chromium release assay, or 
alternatively a non-radioactive assay based on the measurement of lactate 
dehydrogenase, which is released upon cell lysis in the same way as 
51Chromium is released. Target cells will include autologous tumor cells, 
K562, while non-malignant control cells will include autologous T and B-
lymphoblastoid cell lines and autologous fibroblasts, for evaluating the 
auto-aggressive potential of CTLs. Preincubation of target cells with MoAb 
anti-HLA Class I and Class II will be used to assess the specificity of tumor 
cells killing.   
After the achievement of these objectives, the experimental design could 
be transferred to a GMP laboratory to ensure the safety of the autologous 
CTLs activated ex-vivo against tumor and their re-infusion in CRC patients.  
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